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Kidney transplant remains the optimal treatment for majority of patients with end 
stage renal failure. The major challenge facing the transplant community is the 
shortage of organs for donation as demand outstrips supply. This has led to a 
significant change in practice over the last decade with an increasing use of kidneys 
from deceased donors following circulatory death (DCD) and extended criteria 
donors (ECD) that are more susceptible to ischaemic injury.  
 
A period of cold ischemia time (CIT) is an inevitable consequence of organ retrieval 
and transplantation in the process of deceased organ donation. It is well established 
that longer CIT is associated with poorer outcomes following kidney transplantation. 
It is also one of the few potentially modifiable risk factors. It is, therefore, crucial to 
identify and address the factors that adversely affect CIT to enable optimal utilisation 
of available kidneys.  
 
The study investigated multiple factors affecting CIT, involving all aspects of kidney 
journey from retrieval to transplantation to identify areas for improvement.  
 








This is a prospective, longitudinal study over 14 months examining logistical 
pathway of deceased donor kidney transplants in the UK that includes kidney 
allocation, retrieval, transport, histocompatibility testing and preparation of 
recipients for transplantation.  
 
 
Four sets of questionnaires were developed and utilised to encapsulate critical events 
along the kidney timeline with additional data input from the National Health Service 
Blood and Transplant (NHSBT).  
 
Results identified a number of factors that affected CIT, the most important of which 
was adoption of a virtual crossmatch (vXM) policy where appropriate. CIT was also 
reduced significantly if pre-transplant crossmatch (pXM) was performed with donor 
pre-retrieval peripheral blood rather than donor tissues. Significant reduction also 
resulted from use of stored recipient blood for pXM rather than a current sample. 
Other factors that led to increase in CIT in the vXM group were travel times, 
recipients requiring haemodialysis immediately before transplantation and kidney re-
allocation.  
 
This study identifies specific factors that can be addressed to potentially minimise 





















The optimal treatment for majority of patients with end stage kidney failure is kidney 
transplantation. The ever-increasing demand for kidneys for transplantation has led 
to a significant change in practice with increasing use of kidneys that would 
previously have been deemed unsuitable for transplantation, such as kidneys from 
older donors (>60 years), donors with medical conditions such as heart disease and, 
donation after cessation of heartbeat as compared to those from beating-heart but 
brain-dead donors. These kidneys are more susceptible to injury from a period of 
cold storage known as cold ischaemia time (CIT) that which is inevitable in the 
process of transplantation from deceased donors. Longer CIT is associated with 
poorer outcomes following transplantation, such as delay in functioning and failure 
of transplanted kidney. It is, therefore, essential to keep CIT as short as possible to 
enable optimal utilisation of available kidneys.  
 
The study examined multiple logistical factors affecting CIT, such as events at the 
donor hospital, the transport of kidneys to recipient hospital, work carried out in the 
laboratory to establish compatibility of the donor with the recipient, preparation of 
the recipients and availability of operating theatres and relevant staff.  







This study involved prospective collection of data over 14 months, utilising four sets 
of questionnaires that were developed to encapsulate the critical events in the kidney 
timeline. Results identified a number of factors that affected CIT, most important of 
which was relating to transplants in whom compatibility testing between donor and 
recipient in the laboratory was omitted and was deemed safe to proceed without 
waiting for the test to be performed, known as virtual crossmatch (vXM). When the 
 
test was performed before transplant, known as pre transplant crossmatch (pXM), the 
use of donor blood that was obtained prior to retrieval surgery and, the use of stored 
recipient blood rather than a current sample also reduced CIT significantly. In the 
vXM group, travel times, recipients requiring dialysis immediately before transplant 
and repeat allocation of kidneys to a different recipient were significant.  
This study identifies important factors that impact on CIT that can be addressed to 
potentially minimise it and improve outcomes following kidney transplants from 
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1.1 History of renal transplantation 
 
Renal transplantation has evolved over the last century as one of the most significant 
developments in the history of medicine. In the early twentieth century French 
surgeon Alexis Carrel achieved technical success by developing and perfecting the 
method of vascular anastomosis and vessel reconstruction (Linden, 2009). In 1945, 
Peter Medawar identified rejection response and demonstrated that allograft rejection 
was an immunological process (Linden, 2009, Dyer and Johnson, 2004).  
 
The first recorded human organ transplant from deceased donor was performed by 
Russian surgeon Voronoy in 1936 (Dyer and Johnson, 2004). The first successful 
human organ transplant was a kidney from monozygotic twin donor at The Peter 
Bent Brigham Hospital in Boston on December 23rd, 1954 by Joseph Murray and 
John Merrill. Hume transplanted kidney from a deceased donor successfully in 1953 
(Dyer and Johnson, 2004).  
 
In the United Kingdom (UK), Sir Michael Woodruff and his team successfully 
transplanted kidney for the first time from an identical twin at The Royal Infirmary 
of Edinburgh on October 30th, 1960 (Kessaris et al., 2008). A kidney transplant from 




The legal guidelines for brain-stem death were first defined in 1968 by the Ad Hoc 
Committee of the Harvard Medical School, increasing access to organs for 
transplantation. This was later refined in 1981. In 2006, deceased donor organ 
transplantation following donation after cardiac death (DCD) was introduced and 
became acceptable as a means to increase donor organs for transplantation (Linden, 
2009).   
 
In the mid 1960s, it was demonstrated that transplanting kidney to a recipient 
previously exposed to alloantigens led to hyperacute rejection of the transplanted 
organ. This was detected by a crossmatch test between recipient serum and donor 
lymphocytes. This pre-transplant crossmatch test (pXM) was further developed and 
established by Terasaki in 1965. It has since been universally used and has been 
instrumental in avoiding hyperacute rejection by excluding donor-specific 
sensitisation prior to transplantation. Terasaki also developed a microtechnique for 
HLA typing and antibody screening (Dyer and Johnson, 2004, Murray et al., 1976).  
 
The development and use of effective immunosuppression for transplantation has 
evolved from prophylactic total body irradiation in the 1950s to modern and less 
toxic chemical immunosuppressive agents (Murray et al., 1976). The use of 
cyclosporine in 1981 was a landmark in the development of immunosuppression in 
transplant (Dyer and Johnson, 2004). 
 
There has been major progress in both surgical techniques and immunosuppressive 
therapy in transplantation over the last several decades. The quest to minimise organ 
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damage to improve transplant outcomes continues. Belzer in 1967 demonstrated that 
kidneys could safely be stored up to 72 hours by perfusion with plasma at 10 degree  
Celsius continuously. In 1969, Collins introduced storage in ice simplifying the 
process by advances in organ preservation techniques (Dyer and Johnson, 2004).  
 
1.2 Renal transplant versus dialysis 
 
Renal transplantation remains the optimal treatment for the majority of patients with 
end stage renal failure. The development of renal transplantation has been facilitated 
by an increasing awareness of organ donation, advances in organ retrieval, 
allocation, preservation and surgical technique, and significant progress in 
immunosuppression and management of infection post transplant (Neipp et al., 2009, 
Linden, 2009).  
 
Renal transplantation is shown to increase quality of life and reduce comorbidities 
associated with dialysis in several studies (Neipp et al., 2009, Maglakelidze et al., 
2011, Sayin et al., 2007). It is also shown to be associated with longer survival in 
elderly recipients (Bayat et al., 2010, Wolfe et al., 1999). A study comparing cost-
effectiveness between renal transplantation and dialysis has shown significantly 
higher cost in dialysis patients. It also showed significant physical and psychological 
advantage and better quality of life in the transplanted patients (Perovic and 
Jankovic, 2009, Sayin et al., 2007). According to NHS Blood and Transplant 
(NHSBT), the strategic health authority that oversees transplantation in the UK, the 
cost-benefit of kidney transplantation over a ten-year period in the UK compared to 
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dialysis is a quarter of million pounds (NHSBT, 2018c). A study comparing the 
mortality of patients on dialysis awaiting transplantation with those who received 
first deceased donor kidney transplant showed 48% to 82% lower long-term 
mortality rate in the latter (Wolfe et al., 1999). 
 
A systematic review of 110 studies comparing clinical outcomes between kidney 
transplantation and dialysis showed considerable advantage of transplantation over 
dialysis, with significantly reduced mortality and risk of cardiovascular events and 
better quality of life. This was also true despite increase in age and comorbidities 
with the benefits appearing to increase over time (Tonelli et al., 2011).  
 
1.3 Deceased organ donation  
 
Kidney transplantation can be broadly divided into two categories; living donor (LD) 
transplant and deceased donor (DD) transplant, depending on whether the kidney 
was retrieved from a living person or from a deceased donor. 
 
In the UK there are two types of deceased donors who are eligible for organ 
donation. Donors after brainstem death (DBD) are those for whom death was 
confirmed following neurological tests and who had no medical contraindications for 
solid organ donation (NHSBT, 2018a). Donors after circulatory death (DCD) are 
those for whom death was anticipated within four hours after withdrawal of 
treatment and who had no medical contraindications for solid organ donation. The 
clinical categories of DCD include four subgroups described by the Maastricht 
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Classification depending on the circumstances and manner of circulatory arrest 
(NHSBT, 2018b). (Table 1.1) 
 
Table 1.1 The Maastricht classification of donation after circulatory 
death(NHSBT, 2018b) 
Category  Type Circumstances Typical Location 
1 Uncontrolled Dead on arrival Emergency Department 
2 Uncontrolled Unsuccessful 
resuscitation 
Emergency Department 
3 Controlled Cardiac arrest follows 
planned withdrawal of life 
sustaining treatments 
Intensive Care Unit 
4 Either Cardiac arrest in a patient 
who is brain dead 
Intensive Care Unit 
 
The two principal types of DCD are controlled and uncontrolled. Organ retrieval 
following unexpected and irreversible circulatory arrest is referred to as uncontrolled 
DCD and that following planned withdrawal of life sustaining treatment considered 
to be of no overall benefit to the patient is controlled DCD. Uncontrolled DCD organ 
retrieval is currently inactive in the UK (NHSBT, 2018b).  
 
The contribution of DCD organs to overall deceased donor transplantation varies in 
different countries. Some countries including Sweden, New Zealand and Norway do 
not have a DCD programme for transplantation. Countries that do have DCD 
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programmes include the UK, the Netherlands, Australia, Spain and France. In the 
UK, there has been a significant increase in the number of DCDs year on year, over 
the last decade, from 200 donors in 2007-2008 to 584 in 2016-2017 contributing to 
41% of deceased organ donation (NHSBT, 2018b). 
 
The major challenge facing the transplant community is the shortage of organs for 
donation as demand outstrips supply (Rosendale et al., 2002, Audard et al., 2008, De 
Paolis et al., 2016, Solomon, 2011). The patients awaiting transplant are increasingly 
at risk of deterioration and death without a transplant. To meet the ever-increasing 
demand there have been significant changes in practice over the last decade with 
increasing use of organs that would previously have been considered unsuitable for 
transplant (Ojo et al., 2001, Port et al., 2002). These donors are referred to as 
extended/expanded criteria donors (ECD) (Metzger et al., 2003). (Figures 1.2, 1.3) 
 
The United Network of Organ sharing (UNOS) came up with a policy to define the 
ECD by donor characteristics that are associated with a 70% greater risk of kidney 
graft failure when compared to a standard criteria donor (SCD). The aim was to 
maximise the retrieval and use of ECD kidneys by providing mechanisms to 
minimise ECD cold storage time and to expedite ECD kidney allocation (Audard et 







ECD kidney is defined as – 
• All donors equal to or above 60 years of age. 
• Donors equal to or above 50 years of age and less than 60 years of age with 
any two or more of the following risk factors: 




The types of donors for organs are – (Figure 1.1) 
 
LD – living donor 
DD – deceased donor 
DBD – donation after brain death donor 
DCD – donation after circulatory death donor 
SCD – standard criteria donor 























































































Number of deceased donors and transplants in the UK, 1 April 2008 - 31 March 2018,
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A study comparing the mortality rate of ECD kidneys with that of SCD and with 
relevant reference group of similar wait-listed dialysis patients showed that ECD 
kidney transplantation is associated with a significant survival benefit over dialysis 
patients with an increased life expectancy by 5.1 years but lower graft survival of 
53% and patient survival of 74% compared to 67% and 80%, respectively, for SCD 
kidneys (Ojo et al., 2001).  
 
It is well established that younger recipients of kidneys from younger donors have 
superior survival outcome. In an Australian cohort study, it has been shown that 
survival outcome is poorer when ECD kidneys are transplanted in younger recipients 
compared with those with standard criteria donor (SCD) kidneys (Ma et al., 2016). A 
single centre study from Germany also demonstrated that kidneys from old donors 
fared significantly worse in young recipients and significantly better in old recipients 
(Waiser et al., 2000).  
 
1.4 Deceased donor kidney allocation policy 
 
In the UK kidneys from DBD donors are allocated through a National Allocation 
Scheme managed by NHSBT. Kidneys from DCD donors are allocated regionally 
through a National Sharing Scheme where one kidney is offered preferentially to the 
local transplant centre and the second of the pair is shared regionally within four 
defined regions.  Each donor hospital is allocated to one of the four DCD kidney 
sharing regions and offers are restricted to recipients of transplant centres within the 




Table 1.2 DCD kidney sharing regions with designated transplant centres 
(NHSBT, 2017)	
	
North Midlands South West London 
Edinburgh Birmingham Bristol GOSH 
Glasgow Cambridge Cardiff Guy’s 
Leeds Coventry Oxford The Royal Free 
Liverpool Leicester Plymouth The Royal London 
Manchester Nottingham Portsmouth St George’s 
Newcastle Sheffield  WLRTC 
 Belfast   
 
 
Since completion of this study, there has been a change in allocation scheme for 
kidneys from DCD donors; on 3 September 2014, a new National DCD Kidney 
Allocation Scheme was introduced. One kidney from all DCD donors are now 
allocated to local centre and second kidney from donors between 5 and 59 years are 








1.5 Principles of deceased donor kidney allocation scheme 
 
A new National Allocation Scheme for DBD kidneys was introduced in the UK in 
2006 (Johnson et al., 2010a). When the NHSBT is notified of an organ donor, the 
most suitable recipient on the waiting list for deceased donor kidney transplant is 
prioritised for transplant through points-based and evidence-based computer 
algorithm.  
 
The five tiers are (NHSBT, 2017, Johnson et al., 2010a):  
 
A: 000 mismatched paediatric patients – highly sensitised or HLA-DR homozygous 
(complete matches for children – difficult to match patients) 
B: 000 mismatched paediatric patients – others (all except those in Tier A) (complete 
matches for children – others) 
C: 000 mismatched adult patients – highly sensitised or HLA-DR homozygous 
(complete matches for adults – difficult to match patients) 
D: 000 mismatched adult patients – others (all except those in Tier C) (others) 
Favourably matched paediatric patients (100, 010, 110 mismatches) (well matched 
children) 







Within Tiers C, D and E patients are prioritised based on the following points-based 
criteria:  
• Waiting time 
• HLA match and age combined 
• Donor-recipient age difference 
• Location of patient relative to donor 
• HLA-DR homozygosity 
• HLA-B homozygosity 
• Blood group match 
 
This new allocation scheme which is based on evidence base outcomes has been 
hailed as an important contribution to allocation of DBD kidneys in the UK in a 
follow up commentary (Morris and Monaco, 2010). 
 
 
1.6 Reallocation of kidneys 
 
When an accepted kidney cannot subsequently be utilised for the selected recipient it 
is reallocated according to NHSBT policy. It is offered to the next patient on the 
priority list if the kidney has not yet been dispatched to the first transplant centre. If 
it is already dispatched to the first transplant centre, it is offered locally, regionally or 





1.7 Logistics of kidney donation and transplantation in the United 
Kingdom 
	
1.7.1 National Health Service Blood and Transplant (NHSBT) and 
Organ Donation and Transplantation (ODT) 
 
Deceased donor kidney is the most commonly transplanted organ in the UK 
(NHSBT, 2017). The health authority NHSBT and its directorate Organ Donation 
and Transplantation are responsible for coordinating and implementing transplant 
activities across the UK. The ODT maintains the DD kidney transplant waiting list 
and receives notification of potential donors. It mobilises Specialist Nurses for Organ 
Donation (SN-OD) to coordinate the process of donation, manages matching of the 
organs with recipients on the waiting list, offers the organs to suitable recipients and 
directs National Organ Retrieval Service. Its responsibility includes transplant 
outcome data collection for the National Transplant Database (NHSBT, 2018d) .  
 
1.7.2 Specialist nurses for organ donation (SN-OD) 
 
These specialist nurses are responsible for all aspects of the process of donation 
including notification to the Duty Office of potential donors and preparation and 






There are12 regional donor transplant coordinator teams across the UK supporting 
their regional transplant centres –   
 
1. Eastern Region, Cambridge 
2. London Region, London 
3. Midlands Region, Birmingham 
4. Northern Ireland Region, Belfast 
5. North West Region, Liverpool 
6. Northern Region, Newcastle 
7. Scotland Region, Falkirk 
8. South Central Region, Oxford 
9. South East Region, West Sussex 
10. South Wales Region, Cardiff 
11. South West Region, Exeter 












1.7.3 Kidney transplant centres  
 
There are 24 kidney transplant centres in the UK. Some of them are kidney only 
transplant units and the others transplant multiple organs including kidneys. These 
are –  
 
1. Belfast, City Hospital 
2. Birmingham, Queen Elizabeth Hospital 
3. Bristol, Southmead Hospital 
4. Cambridge, Addenbrooke’s Hospital 
5. Cardiff, University Hospital of Wales 
6. Coventry, University Hospital 
7. Edinburgh, Royal Infirmary 
8. Glasgow, Western Infirmary 
9. Leeds, St James’s University Hospital 
10. Leicester, General Hospital 
11. Liverpool, Royal Liverpool University Hospital 
12. London, Great Ormond Street Hospital 
13. London, Guy’s Hospital 
14. London, St George’s Hospital 
15. London, The Royal Free Hospital 
16. London, The Royal London Hospital 
17. London, West London Renal and Transplant Centre (Hammersmith Hospital) 
18. Manchester, Royal Infirmary 
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19. Newcastle, Freeman Hospital 
20. Nottingham, City Hospital 
21. Oxford, Churchill Hospital 
22. Plymouth, Derriford Hospital 
23. Portsmouth, Queen Alexandra Hospital 
24. Sheffield, Northern General Hospital  
 
City Hospital, Belfast was not included in the study. Great Ormond Street Hospital 
and Guy’s Hospitals were considered as one unit. Eleven of the 22 transplant centres 
included were kidney only transplant centres and the other 11 were multi-organ 
















Table 1.3 Kidney only transplant centres and multi-organ transplant centres 
Kidney Only Transplant Centres Multi-organ Transplant Centres 
Coventry, University Hospital 
Coventry and Warwick 
Birmingham, Queen Elizabeth 
Hospital 
Glasgow, Western Infirmary Cambridge, Addenbrooke's Hospital 
Leicester, Leicester General 
Hospital 
Cardiff, University Hospital of 
Wales 
Liverpool, Royal Liverpool 
University Hospital 
Edinburgh, Royal Infirmary 
London, St George's Hospital 
Leeds, St James's University 
Hospital 
London, The Royal London 
Hospital 
London, Guy's Hospital 
Nottingham, City Hospital London, The Royal Free Hospital 
Plymouth, Derriford Hospital 
Manchester, Manchester Royal 
Infirmary 
Bristol, Southmead Hospital Newcastle, Freeman Hospital 
Sheffield, Northern General 
Hospital 
Oxford, Churhill Hospital 
Portsmouth, Queen Alexandra 
Hospital 







1.7.4 Histocompatibility and Immunogenetics laboratories  
 
There are 20 Histocompatibility and Immunogenetics (H&I) laboratories in the UK 
supporting regional transplant centres and these are responsible for tissue typing 
(TT) and crossmatching of the donor and recipient tissues and serum to establish 
HLA typing and compatibility of the donor organ and the recipient for 
transplantation. The laboratories are –  
 
1. Birmingham, NHSBT  
2. Bristol, Southmead Hospital 
3. Cambridge, Addenbrooke’s Hospital 
4. Edinburgh, SNBTS  
5. Glasgow, Gartnaval Hospital 
6. Leeds, St James’s University Hospital 
7. Leicester, General Hospital 
8. Liverpool, Royal Liverpool University Hospital 
9. London, Guy’s Hospital 
10. London, Royal Free Hospital 
11. London, Royal London Hospital 
12. London, Hammersmith Hospital 
13. London, NHSBT Tooting 
14. Manchester, Royal Infirmary 
15. Newcastle, NHSBT 
16. Northern Ireland, Blood Transfusion Service 
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17. Oxford, Churchill Hospital 
18. Plymouth, Derriford Hospital 
19. Sheffield, NHSBT 
20. Wales, Welsh Blood Service 
 
Each H&I laboratory supports transplants in a single transplant centre with the 
exception of 4 laboratories. NHSBT Birmingham supports Birmingham and 
Coventry and Guy’s Hospital H&I laboratory supports Guy’s Hospital, Great 
Ormond Street Hospital and part of St George’s Hospital transplants. NHSBT 
Tooting supports Portsmouth Hospital and part of St George’s Hospital transplants 
















Table 1.4 List of H&I laboratories and the corresponding transplant centres 




Bristol, Southmead Hospital Bristol 
Cambridge, Addenbrooke’s Hospital Cambridge 
Edinburgh, SNBTS Edinburgh 
Glasgow, Gartnaval Hospital Glasgow 
Leeds, St James’s University Hospital Leeds 
Leicester, General Hospital Leicester 
Liverpool, Royal Liverpool University 
Hospital 
Liverpool 
London – Guy’s Hospital 
London – Guy’s 
London – GOSH 
London – St George’s 
London – NHSBT Tooting  
Portsmouth 
Manchester, Royal Infirmary Manchester 
Newcastle, NHSBT Newcastle 
Northern Ireland, Blood Transfusion Service Belfast 
Oxford, Churchill Hospital Oxford 




Wales, Welsh Blood Service Wales 
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1.7.5 Transplant centre teams 
 
Each transplant unit consists of a multidisciplinary team of specialists including 
Recipient Coordinators, Transplant Surgeons and Specialist Registrars, 
Nephrologists, H&I Staff and, Ward and Theatre Staff. In majority of the transplant 
units, deceased donor Recipient Coordinators (RC) are responsible for organisation, 
support, guidance and preparation of potential recipients in the process of kidney 
transplantation.  
 
1.8 Potential donors 
When a potential donor is identified, SN-ODs notify ODT and arrange collection and 
dispatch of donor blood sample to local H&I laboratory for HLA typing. The result 
of the HLA typing is then faxed to the ODT who undertake a computerised match 
run against the wait-listed potential recipients using a complex algorithm and this 
provides a shortlist of potential recipients.  
 
1.9 Establishing donor and recipient compatibility  
 
HLA matching is performed to determine the degree of histocompatibility between a 






1.9.1 Determining donor and potential recipient HLA type 
 
The human leucocyte antigen (HLA) molecules are membrane bound glycoproteins 
that play a central role in antigen presentation and recognition in immune response 
regulation (Howell et al., 2010). The genes coded for HLA molecules are located on 
the short arm of chromosome 6 which is also known as major histocompatibility 
complex (MHC). HLA class I and class II genes are involved in the transplant 
immune response. Donors and potential recipients, before being wait-listed for 
transplantation, are HLA typed for class I (HLA-A, -B and -C) and class II (HLA-
DR, -DQ) genes by DNA based technology (Dyer, 2008). Donor HLA type is 
determined locally using donor peripheral blood obtained prior to organ retrieval 
(Taylor et al., 2000). 
 
There are two methods for determining the HLA type: serological, which is based on 
detection of genetic variation in the expressed HLA molecules and DNA based 
technique (Howell et al., 2010). Typing with the DNA-based method is more 
accurate than serological method; sample testing can be repeated when required as 
DNA is easily stored and it does not require live lymphocytes (Cecka, 2009).  
 
1.9.2 Potential recipient HLA antibody screening 
 
All patients on the transplant waiting list are regularly screened for HLA 
alloantibodies to identify any unacceptable donor HLA antigens to which anti-donor 
antibodies may be present in the sera and hence avoid positive XM and unnecessary 
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transport of kidneys. Equally, in absence of HLA specific antibodies, transplantation 
can safely proceed without a prospective crossmatch (XM), also called virtual 
crossmatch (vXM). Patient samples are screened on a 3 monthly basis for routine 
antibody monitoring according to BTS guidelines as their sensitisation may vary 
over time. Samples are also screened for potential sensitisation between two and four 
weeks following transfusion, pregnancy or transplantation (BTS-BSHI, 2015, Taylor 
et al., 2010).  
 
There are various methods for HLA specific antibody detection and characterisation. 
Cell based assays such as complement dependent cytotoxicity (CDC) use 
lymphocyte panels of HLAs representing the donor population (Taylor et al., 2010). 
Solid-phase immunoassay (SPI) does not require viable lymphocytes and 
complement and also provides greater sensitivity than CDC assay of which Luminex 
assay is considered gold standard (Howell et al., 2010, Tait et al., 2013, BTS-BSHI, 
2015). CDC assay is still used for screening and crossmatching in supplement to 
Luminex assay (BTS-BSHI, 2015, Tait et al., 2013).   
 
1.10 Immediate pre-transplant donor- recipient compatibility 
assessment  
 
Crossmatching test is performed prior to transplant to identify unacceptable 
antibodies in the recipient serum that are reactive with donor lymphocytes and, 




1.10.1 Pre-transplant laboratory crossmatch test 
 
Pre-transplant crossmatching (pXM) is performed to establish compatibility between 
the donor and potential recipient using two methods; complement dependent 
cytotoxicity (CDC-XM) and flow cytometry (FC-XM). These tests are used to 
confirm the presence or absence of donor specific antibodies (DSA) in the recipient 
serum against the donor lymphocytes (Howell et al., 2010, Cecka, 2009). Crossmatch 
test can be performed with historical recipient sample, without the need of waiting 
for a current sample to be available, if there is no recent history of sensitising events 
(Cecka, 2009). Donor lymphocytes are isolated from pre-retrieval peripheral blood 
that was obtained for HLA typing, or from spleen and/or lymph nodes following 
organ retrieval (BTS-BSHI, 2015). It takes between 4 and 6 hours to perform the 
pXM (Taylor et al., 2010). 
 
1.10.2 Virtual crossmatch 
 
In some carefully selected recipients, kidney transplantation can safely proceed 
without the need for a pre-transplant crossmatch test (Taylor et al., 2000, Dyer and 
Taylor, 2000, Taylor et al., 2010, Tambur et al., 2009). A negative crossmatch 
between donor and recipient can be predicted if the recipient has clearly defined 
stable HLA-specific antibodies, negative screening history and no recent history of 
sensitising events which is described as virtual crossmatch (vXM) (Cecka, 2009, 




A virtual crossmatch policy in deceased donor kidney transplants was first 
introduced in the UK in Cambridge two decades ago (Taylor et al., 2000). In 2010, 
they published a large ten-year prospective study demonstrating safe application of 
vXM policy routinely on recipients with low sensitisation in deceased donor kidney 
transplantation (Taylor et al., 2010). The study included a total of 606 deceased 
donor kidney transplants, 42% of which went ahead with a vXM. A retrospective 
XM was performed in each case to confirm the negative prediction. More recently, a 
Spanish study examining the results of implementation of a national priority 
allocation system based on vXM for highly sensitised patients found that it was 
highly effective in increasing their access to transplantation (Valentin et al., 2016).  
 
The results of the final crossmatch test are carefully reviewed by histocompatibility 
expert and discussed with the transplanting surgeon or nephrologist to review any 
relevant risk factors before proceeding with transplant (Dyer and Taylor, 2000). 
 
At the time of this study, all UK H&I units with the exception of H&I units at 









1.11 Ischaemia-reperfusion injury 
 
Ischaemia-reperfusion injury is inevitable in deceased donor kidney transplantation 
as a consequence of interruption and subsequent re-establishment of blood flow to 
the organ and influences clinical outcomes such as early graft rejection (Salvadori et 
al., 2015). Renal ischaemia occurs early in the retrieval process when blood flow to 
kidney is interrupted when the aorta is clamped. This leads to initial short period of 
severe hypoxic tissue injury that initiates a series of events at the cellular and 
molecular level leading to micro-vascular dysfunction (van der Vliet and Warle, 
2013, Salvadori et al., 2015). The ischaemic injury is further compounded by a 
longer period of hypothermic perfusion and storage leading to further cellular 
dysfunction (Salvadori et al., 2015, Zhao et al., 2018, Pratschke et al., 2008). 
Revascularisation of the kidney at transplantation restores the blood supply and 
oxygenation to the tissues but, paradoxically, triggers a complex sequence of events 
associated with apoptosis, endothelial injury and innate and adaptive immune 
response, thus aggravating the damage and leading to structural impairment at 
cellular level and cell death (Pratschke et al., 2008, Salvadori et al., 2015). There is a 
strong association between severity of early graft failure and severity of ischaemia-







1.12 Delayed graft function  
 
Delayed graft function (DGF) is an early clinical manifestation of a transplanted 
kidney when it fails to function in the immediate post-transplant period due to 
ischaemia-reperfusion and immunological injuries sustained in the process of 
retrieval and transplantation (Yarlagadda et al., 2008, Ditonno et al., 2013, Moreso et 
al., 1999, Jung et al., 2010). There is no standardised definition of delayed graft 
function (DGF) in the literature. The definition of DGF is either dialysis based or 
creatinine based or a combination of dialysis, creatinine and urine output. Some of 
the studies have defined it as failure of serum creatinine to fall by less than 10% a 
day for three consecutive days while others define it as biopsy proven acute tubular 
necrosis (ATN) or, serum creatinine decreasing by less than 1.1mg/dL in the first 
five days. A systematic review of definition of DGF identified 18 unique variations 
in the definition and diagnosis of DGF. However, the majority of the studies have 
defined DGF as requirement for dialysis in the first week post-transplant 
(Yarlagadda et al., 2008, Rosenthal et al., 1991, Perico et al., 2004, Ditonno et al., 
2013, Daly et al., 2005, Jung et al., 2010).  
 
There is wide variation in the incidence of DGF ranging from 5% to 50% in 
deceased donor kidney transplantation (Ojo et al., 1997, Yarlagadda et al., 2008, 
Perico et al., 2004). This has not improved despite major advances in transplantation 
(Yarlagadda et al., 2008, Chapal et al., 2014, Sharif and Borrows, 2013). DGF is 
known to be associated with poorer outcomes including acute and chronic graft 
rejection, chronic allograft nephropathy, decreased graft survival and graft loss 
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(Yarlagadda et al., 2008, Yarlagadda et al., 2009, Troppmann et al., 1995). This leads 
to considerable morbidity, requirement of additional immunosuppression, 
radiological studies and biopsies leading to prolonged hospital stay and potential 
return to dialysis, which have considerable financial implications and poorer long-
term survival (Yarlagadda et al., 2008, Ojo et al., 1997, Rosenthal et al., 1991, 
Ditonno et al., 2013, Freedland, 1999, Cecka, 2001, Marcen et al., 1998).   
 
Results of studies evaluating the impact of DGF on kidney transplant outcomes are 
controversial with some studies indicating minimal or no impact on graft survival 
and others associating it with poor long-term graft survival (Ojo et al., 1997). In a 
large study, Ojo et al found that DGF was significantly associated with reduction in 
short and long-term graft survival. It not only exacerbated the effect on allograft 
survival but also had greater impact than HLA matching on post transplant outcomes 
(Ojo et al., 1997). Another study by Butala et al found strong evidence suggestive of 
causal effect of DGF on graft failure and mortality at 1 and 5 years (Butala et al., 
2013). A meta-analysis by Yarlagadda et al showed 41% more risk of graft loss at 
3.2 years and 38% relative increased risk of acute rejection compared to patients 
without DGF (Yarlagadda et al., 2009).  
 
In the current scenario of organ shortage and increasing use of ECD kidneys, it is 
important that we adopt all possible measures to decrease the incidence of DGF to 
mitigate its short and long term impact on transplanted kidneys (Yarlagadda et al., 
2009, Chapal et al., 2014, Perico et al., 2004, Moreso et al., 1999). Minimising 
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ischaemic injury by reducing cold storage time and improving organ preservation 
pre-transplant are important factors in reducing the risk of DGF (Gill et al., 2014).  
 
1.13 Kidney preservation (Machine perfusion versus cold storage) 
 
Preservation of donor kidneys for transplant involves either static cold storage or 
dynamic machine perfusion (Hameed et al., 2016). Although machine perfusion was 
used several decades ago in conjunction with static cold storage, there has been 
resurgence in their use in the last decade especially because of increasing use of 
DCD and ECD kidneys for transplantation (Hameed et al., 2017, Yuan et al., 2010). 
Preservation of organs with machine perfusion is still evolving and cold storage 
remains the principal method of kidney preservation prior to deceased donor kidney 
transplant (Hameed et al., 2016, Lam et al., 2013). There are different techniques 
used for machine perfusion, namely, hypothermic machine perfusion, oxygenated 
machine perfusion and normothermic machine perfusion (Jochmans et al., 2015). 
Factors such as ideal perfusate solution, optimum temperature and timing for 
machine perfusion are currently undetermined (Kaths et al., 2018, De Deken et al., 
2016). It is apparent that kidneys with different baseline risks require different 
preservation techniques (Jochmans et al., 2016). 
 
Machine perfusion in transplantation is still evolving and remains widely debated 
(Jochmans et al., 2016, Jochmans et al., 2017). An international randomised 
controlled trial (RCT) comparing hypothermic machine perfusion with cold storage 
of deceased donor kidneys showed reduced risk of DGF and better 1-year graft 
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survival after machine perfusion. DBD kidneys showed better survival at 3 years 
post-transplant, especially in ECDs but DCD kidneys showed no graft survival 
benefit after machine perfusion compared to cold storage (Moers et al., 2009, Moers 
et al., 2012). A large registry data analysis examining pulsatile machine perfusion 
and DGF found reduced risk of DGF with machine perfusion in all deceased donor 
kidneys regardless of the length of cold storage (Gill et al., 2014). However, other 
studies have not shown consistency in graft survival with machine perfusion (Sandal 
et al., 2018). A systematic analysis of seven RCTs showed no effect of machine 
perfusion on primary non-function (PNF), graft loss and patient death at 1-year for 
DBD and DCD kidneys despite significant reduction in DGF (Lam et al., 2013). A 
recent study of large registry data analysis showed no benefit of machine perfusion 
in kidney transplant outcomes beyond 1 year. It questions the use of machine 
perfusion in deceased donor kidney transplant as it showed no long-term benefit 
especially in ECD and DBD kidneys (Sandal et al., 2018). Another multicentre RCT 
from the UK comparing cold machine perfusion with static cold storage of DCD 
kidneys showed no difference in the incidence of DGF. Also, there was no advantage 










1.14 Cold ischaemia time  
  
Cold ischaemia time (CIT) is defined as the time interval between in situ cold 
perfusion of the kidney at donor operation and removal from ice for anastomosis at 
recipient operation (Sweny, 2017, van der Vliet and Warle, 2013, van der Vliet et al., 
2011). 
 
A period of CIT is unavoidable in the process of deceased donor kidney 
transplantation. It requires the retrieved kidneys to be stored in ice to reduce the 
metabolic demands until they can be transplanted.  This allows the kidneys to be 
shipped to a different centre for transplantation to best-matched recipients in 
accordance with the national allocation policy.  
	
1.14.1 Why is Cold Ischaemia Time important?  
 
Cold ischaemia time is one of the most important factors that influence outcomes 
after deceased donor kidney transplants. It is known to be the principle predictor of 
DGF (Cecka, 2001, Ojo et al., 1997). 
 
A study analysing factors influencing outcome after DBD kidney transplants in the 
UK to inform the new Kidney Allocation Scheme identified CIT to have a strong 
influence on short-term graft outcome with a 4% increase in risk of graft failure for 
each additional hour of CIT beyond 21 hours. CIT was prolonged by reallocation and 
exchanges of kidneys between distant transplant centres. CIT increased by 30 
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minutes on average when a kidney was declined by the centre to which it was 
initially offered. When a kidney was accepted by a centre for a patient but was 
subsequently reallocated and transplanted in another recipient at the same centre, 
CIT increased by an average of 7 hours. CIT increased by 2 hours in the case of long 
distance kidney exchanges between different UK centres (Johnson et al., 2010b).   
 
A UK-wide cohort analysis of factors affecting outcome of DCD kidney transplants 
demonstrated that prolonged CIT is associated with poorer outcome with doubling of 
the risk of graft failure for CIT beyond 12 hours. CIT was also the only variable that 
was potentially modifiable (Summers et al., 2010).  
 
Another cohort study that explored the effect of donor age and CIT on outcome 
comparing kidneys from DCD and DBD donors in the UK showed that prolonged 
CIT was associated with reduced graft survival for DCD but not DBD kidneys. DCD 
kidneys showed more susceptibility to cold ischemic injury as longer CIT was 
associated poorer graft survival. DGF was significantly higher in kidneys from DCD 
donors (49%) than those from DBD donors (24%) (Summers et al., 2013). 
 
A French cohort study of relationship of CIT with the transplantation outcomes in 
DBD kidney transplants highlighted the importance of CIT by demonstrating a 
strong and proportional increase in the risk of graft failure for each additional hour of 
CIT. It also showed a proportional relationship between each additional hour of CIT 
and the risk of recipient death (Debout et al., 2015). This relationship that associates 
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even a small increase in CIT with worse outcome has been highlighted in a 
subsequent commentary (Ponticelli, 2015).  
 
Other studies have highlighted different thresholds for CIT beyond which the risk for 
graft failure increased (Johnson et al., 2010b, Summers et al., 2013, Kayler et al., 
2011a, Opelz and Dohler, 2007). Data from the outcome of a large multinational 
collaborative study of 91,674 deceased donor kidney transplants shows that CIT 
beyond 18 hours threshold is detrimental to the graft outcome. The study also 
supports and justifies the exclusive use of simple cold storage as a means for 
preservation (Opelz and Dohler, 2007). Similar study by Doshi et al on paired 
kidneys showed progressively worsening effect on early graft outcome with CIT 
beyond 12 hours (Doshi et al., 2011). 
 
1.14.2 Implications of prolonged Cold Ischaemia Time on kidney 
transplant outcomes 
 
There is a plethora of evidence in published national and international studies 
demonstrating the association between prolonged CIT and its effect on short and 
long-term graft function, graft survival and acute rejection in deceased donor kidney 
transplants. Several studies have shown that CIT is an independent risk factor for 
DGF (Ojo et al., 1997, Doshi et al., 2011, Tandon et al., 2000). Whilst the 
association between prolonged CIT and short-term outcome is well established its 




A study reviewing the implications of prolonged CIT identified its negative effect on 
the short-term graft outcome, especially with ECD and DCD kidneys, but it had no 
effect on long-term function and graft survival. It also found that DGF was 
associated with higher rate of acute rejection (AR) (van der Vliet and Warle, 2013).  
A retrospective cohort study of 5382 kidney recipients using United Network for 
Organ Sharing (UNOS) data on paired kidneys showed that the one that developed 
DGF had longer CIT. This was confirmed by multivariate analysis. DGF was also 
associated with AR in the first 6 months in a third of the recipients (Doshi et al., 
2011). 
 
Another cohort study of paired kidneys transplanted on 14 230 different recipients 
using data from Scientific Registry of Transplant Recipients showed that the 
incidence of DGF was significantly associated with longer CIT in ECD kidneys. 
However, it did not have any effect on graft survival and there was no association of 
AR with CIT (Kayler et al., 2011a). 
 
A single-centre retrospective study by Mikhalski et al of 611 kidney transplant 
recipients who received modern immunosuppressive therapy demonstrated that 
longer CIT was an independent predictor for DGF by multivariate analysis. 
Prolonged CIT but not DGF was also an independent predictor of AR in multivariate 
analysis with 4% increase in the risk of AR with each additional hour of CIT. It was 
also an independent predictor of graft loss with respect to death-censored graft 




Another single-centre study by Quiroga et al concluded that CIT was the most 
important independent predictor of poor short and long-term graft survival with 
significant influence on DGF and graft survival. There was no specific threshold for 
CIT beyond which its deleterious effect accelerated but its effect appeared to be 
linear with progressive increase in the incidence of DGF with each additional hour, 
even at short CIT (Quiroga et al., 2006). 
 
Longer CIT was shown to be associated with increased risk of DGF and AR and had 
a long-term impact on graft function and survival in another single centre study 
(Bronzatto et al., 2009).  
 
A retrospective study of a cohort of 6322 recipients of DBD and DCD kidneys using 
Dutch Organ Transplant Registry data also found that CIT was an independent risk 
factor for DGF in multivariate analysis with shorter CIT associated with better graft 
survival in both DBD and DCD recipients (van der Vliet et al., 2011).  
 
Poorer long-term graft survival was seen in a Spanish retrospective cohort study of 
1395 deceased donor kidney transplants evaluating the association between the 
duration of CIT and graft outcome in younger donors (<50 years). It found that there 
was a marked association between longer CIT and death-censored graft failure 
independent of AR and DGF. Recipients with longer CIT also had an increased rate 
of AR, DGF and graft loss. They also found a linear association between increase in 
CIT and graft failure with 20% increase in graft failure for every 5 hours increase in 
CIT, most marked above 19 hours (Hernandez et al., 2008).  
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Ojo et al, in a multivariate analysis of data from the US Renal Data System, showed 
that prolonged CIT was the most important predictor of DGF with 23% increase in 
the risk with every 6 hours increase of CIT. DGF had a linear relationship with CIT, 
the risk of which increased with increasing CIT. DGF and AR were strong 
independent predictors of short and long-term graft failure. Prolonged CIT was also 
found to be an independent risk factor for reduced long-term graft survival (Ojo et 
al., 1997). 
 
A systematic review and meta-analysis to determine the association between DGF 
and graft outcomes found detrimental association of DGF on long-term graft 
function and survival and AR (Yarlagadda et al., 2009). 
 
A large, prospective, multicentre study in France revealed that CIT of >12 hours was 
an independent and significant factor in reduced long-term graft survival in ECD 
transplants (Aubert et al., 2015). 
 
Several other studies have also demonstrated direct or indirect association between 
CIT and short and long-term outcomes in deceased donor kidney transplants (Warle 
et al., 2009, Roodnat et al., 2003, Asderakis et al., 2001, Bronzatto et al., 2009, 
McLaren et al., 1999, Connolly et al., 1996). 
 
Despite this evidence, and although it is long established that prolonged CIT 
predisposes to DGF, CIT as an independent predictor for long-term graft outcome is 
still debated (Aubert et al., 2015, Kayler et al., 2011a, Kayler et al., 2017, Wang et 
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al., 2017). A multivariate analysis using data of a cohort of 18 164 paired kidneys 
from Scientific Registry of Transplant Recipients showed no difference in graft 
survival regardless of the difference in the length of CIT of 15 hours or more 
between the two kidneys. This was demonstrated in spite of a strong association 
between longer CIT and DGF but not between CIT and AR (Kayler et al., 2011b).  
 
Another retrospective cohort study of paired kidneys from DCD donors transplanted 
into two separate recipients with different CITs, with data from US registry, found 
no effect of prolonged CIT on long-term graft outcomes. Also, there was no 
association between CIT and AR in the study (Kayler et al., 2017). Similar outcome 
was also seen in a UK study of impact of CIT on transplant outcomes in DCD 
kidneys where prolonged CIT did not affect patient and graft survival or long-term 
graft outcome (Pine et al., 2010). Another UK study of sequential paired DCD 
kidney transplants showed similar results. Although kidneys that were transplanted 
later had a higher incidence of DGF, this did not affect long-term graft or recipient 
survival (Goldsmith et al., 2010). 
 
It is evident from the majority of these studies that there is a clear need to ensure that 
CIT remains as short as possible because poorer graft outcome increases morbidity, 
prolongs hospital stay, necessitates further immunosuppression and dialysis with 
significant financial ramifications.  
 
There are several other risk factors that can also impact on outcomes following 
deceased donor kidney transplants. These include donor factors such as donor body 
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weight, donor age, donor type, e.g., DBD, DCD, ECD, number of previous grafts; 
recipient factors such as recipient body weight, waiting time on dialysis prior to 
transplant and HLA mismatches (Jung et al., 2010, Barlow et al., 2009, Johnson et 
al., 2010b, Pieringer and Biesenbach, 2005, Goh et al., 2009, Summers et al., 2010).  
 
In the current climate of improving immunosuppression and increasing use of DCD 
and ECD kidneys to narrow the gap between demand and supply, CIT remains one 
of the few modifiable risk factors that can reduce the negative impact on these 
kidneys when there is little choice (Perico et al., 2004, Bahde et al., 2014).  
 
1.14.3 What are the factors that affect Cold Ischaemia Time? 
 
Although there are several studies exploring the impact of prolonged CIT, there are 
only a few that investigate factors that contribute to CIT.  
 
A French study analysed the influence of using a timesheet on CIT over a 2-year 
period and compared the result with the preceding 2 years. The individual timesheet 
for each kidney transplant was adapted to record time of interventions by all 
department personnel involved. Several parameters were collected and analysed to 
identify points of delay. Interestingly, they managed to significantly reduce the 
median CIT simply by implementing the timesheet, from 21.45 hours in the previous 
2 years to 13.27 hours. The major limiting factor for transplant was the availability of 




In another French study, Joseph et al studied various stages of kidney retrieval 
process to transplantation. The time at which tissue was obtained for typing, which 
was performed at the time of kidney retrieval, was the principal factor that prolonged 
CIT. This could be reduced by 7 hours if HLA typing and crossmatching was 
performed while the donor was still in intensive care unit rather than during organ 
retrieval (Joseph et al., 2003).  
 
A Chilean study investigating modifiable factors at various stages of kidney 
transplant identified a number of organisational and logistical issues and 
crossmatching policy that affect transplant outcomes. They found that by obtaining 
samples for HLA typing and crossmatching before retrieval was important in 
shortening the CIT. The shortest CITs were observed in kidneys transplanted locally 
when samples were sent locally for HLA typing and crossmatching (Elgueta et al., 
2010).  
 
Salahudeen et al demonstrated reduction of CIT during a 10-year study period in the 
US associated with improved kidney transplant outcomes despite lack of policy on 
procedural changes having been instituted to minimise CIT. They speculate that 
exogenous factors such as improved communication, better laboratory facilities, 
speedier transportation, greater efficacy in retrieving, transporting and transplanting 
could be attributed to decreased CIT. There was a possibility that transplant 
communities were perhaps aware of the ongoing study and were mindful of avoiding 
prolonged CIT in the context of increasing use of DCD and ECD kidneys 
(Salahudeen and May, 2008). 
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A retrospective Korean study of deceased donor kidney transplants showed a 
remarkably short mean CIT of 3.8+/-2.2 hours, which is markedly shorter than CITs 
in studies from other countries. This was attributed to several factors, namely, 
starting retrieval surgery only after completion of kidney allocation, short travelling 
distance within the specified national regions, simultaneous preparation of recipient 
at the time of donor surgery and prompt transplantation after kidney delivery and 
back-table preparation (Kim et al., 2013). 
 
Ziaja et al also showed that early donor lymph node retrieval and local or central 
HLA typing and crossmatching significantly shortened CITs. (Ziaja et al., 2006) 
 
A Hungarian study demonstrated that with protocol changes for donor HLA typing 
and prospective crossmatching using donor peripheral blood before declaration of 
brain death and, with recipient preparation starting before retrieval surgery, it was 













Kidney transplant is a highly effective treatment for many patients with end stage 
renal failure. The shortage of organs for donation remains a major challenge, and has 
led us to accept organs for transplantation that we would have declined a decade ago. 
With increasing use of organs from DCD and ECD donors, it is beholden upon us to 
optimise the outcomes from each transplant. Cold ischaemia time is one of the few 
modifiable factors affecting outcome of kidney transplant.  
 
This study sought to investigate factors that affect CIT in the process of deceased 




The aims of the present study were: 
  
• To undertake comprehensive review of logistical factors in transplant centres 
in the UK and, their impact on CIT in deceased donor kidney transplants 
• To determine whether there are specific areas to focus efforts on to reduce 
CIT 






2.1 Study design 
 
This is a prospective, longitudinal study of logistical factors influencing cold 
ischaemia times in deceased donor kidney transplants performed over a 14-month 
period between 1st June 2011 and 31st July 2012. This included kidney only (single, 
double, en-bloc) and simultaneous pancreas and kidney (SPK) transplants from 
donation after brain death (DBD) and donation after circulatory death (DCD) donors 
and excluded living donor kidney transplants, kidneys transplanted with organs other 
than pancreas and transplants that did not proceed despite retrieval of organs. When 
2 kidneys were transplanted in a single recipient (dual kidney transplant), the one 
with the longer cold ischaemia time (CIT) was excluded. Data on recipients and 
theatre times that were inconsistent with the rest of the data and those that had a 
discrepancy of more than 1 hour from NHSBT data were excluded (n=52 
transplants).  
 
The study was funded from a research grant from National Health Service Blood and 
Transplant (NHSBT), and was approved by the Kidney Advisory Group, which 






2.2 Project collaboration 
 
A steering group was formed, exclusively for the study, which included Consultant 
Transplant Surgeon and Consultant Clinical Scientist from University of Edinburgh, 
Professor of Transplantation Surgery and Consultant Clinical Scientist from 
University of Cambridge, Principal Statistician from NHSBT and Clinical Fellow. 
The group met at key periods of the study at the interval of 3 to 6 months. It met 
initially to inform the overview of the study and to discuss practicalities and 
development of proforma for data collection, then to finalise the proforma and to 
plan the next steps to take the project forward. The group met again on completion of 
the study to analyse the results and to inform the findings. There were also regular 
weekly meetings between the Clinical Fellow and the supervisors to provide an 
update on the progress of the study, to discuss and address difficulties encountered in 




The variables included in the data were continuous and categorical data.  Continuous 
data included series of time intervals between donor notification and completion of 
transplantation surgery. Categorical data included type of donor, transplant units, 
Histocompatibility and Immunogenetics (H&I) laboratories, type of crossmatch, 





2.4 Kidney timeline 
 
Study of all aspects of kidney journey from donor to recipient formed the basis of the 
study. Questionnaires were developed to capture the crucial points on the kidney 
timeline for each deceased donor (DD) kidney from time of donation at donor 
hospital to completion of transplantation in recipient.  
 
Five key logistical areas were identified, namely, activities around donor operation 
(Donor), organ transport (Transport), laboratory tests (H&I), recipient preparation 
(Recipient) and theatre (Theatre). Different factors within each of these key areas 





















Figure 2.1 Summary of logistical factors that might contribute to cold ischaemic 
















































2.5 Involvement of Organ Donation and Transplantation (ODT), NHS 
Blood and Transplant (NHSBT) and the Duty Office (DO) services 
 
At the outset, a visit to the Organ Donation and Transplantation (ODT) and NHSBT 
in Bristol was undertaken.  
 
The aim of the visit was -  
• To gain knowledge of how the Duty Office works 
• To gain knowledge of support the statistical division provides for 
transplantation 
• To gain knowledge of available data from the National Transplant 
database  
• To find out how data could be accessed and how they should be 
analysed 
• To identify key personnel for involvement in the study 
• To identify information already collected by ODT to avoid 
duplication of data collection 
 
At the time of the visit, anonymisation of donor and recipient details and methods to 
ensure accurate data collection was obtained for timings were discussed. It was 
agreed that some of the information could be added to the ODT form for donor 
information. Ways of obtaining information for transport times was discussed and 
agreed to contact the transport providers, including Transport for Transplant (TFT) 
and Amvale, to see what information they collect. An outline for data protection was 
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agreed following discussion with the Data Protection Information Manager at ODT 
and documented for each stage of the study.  
2.6 Data protection  
 
Following discussion with the ODT Information Manager, the following measures 
were agreed upon and adopted to ensure data protection: 
1. All donor and recipient details were fully anonymised by using only unique 
donor and recipient ODT numbers so that the data set would not contain any 
patient identifiable information. 
2. The main database was stored in NHS Lothian computer with central server 
backup on a shared drive with controlled access. It was only accessible to the 
student and the supervisors. Data were also stored in the encrypted University 
laptop provided. 
3. All the paper records were kept in the cabinet of a locked room at the Royal 
Infirmary of Edinburgh throughout the study period. 
4. On completion of the study, the paper and electronic records would be 
returned to NHSBT for disposal. 
 
2.7 Ethical approval 
 
Advice was sought for ethical approval from the South East Scotland Research and 
Ethics Service. It was informed that the study did not require NHS ethical approval 
under the terms of the Governance Arrangements for research Ethics Committees in 
the UK. (Appendix 2) 
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2.8 Pilot study 
 
A pilot study was set up to find out whether the data collection forms were fit for 
purpose and to identify areas of difficulties that would have to be addressed to ensure 
accurate and timely collection of relevant data. It was undertaken for 4 months 
between January and end of April 2011. The study was introduced locally to the 
transplant team including transplant surgeons, nephrologists, SN-ODs and recipient 
coordinators. Four transplant centres, (Edinburgh, Cambridge, Glasgow and 
Nottingham) and their associated H&I laboratories (Edinburgh, Cambridge, Glasgow 
and Sheffield) and Oxford H&I laboratory piloted the study.  Two Regional Donor 
Coordinator team (Scottish Organ Donation and Eastern Regional Organ Donation) 
serving the participating centres also participated. Each of the piloting centres was 
visited personally to introduce the study and to encourage participation. The 
overview of the study was introduced and the data collection forms were explained 
to the lead for each centre and as many of the team members as possible. A key 
contact person was identified in each centre and communicated with regularly to 
address any queries or difficulties.   
 
A link person was identified in each centre to take the ownership of the process. A 
dry run of data collection was undertaken with one of the local Recipient 




At the time of collecting data, the teams were regularly given feedback with 
information about the gaps in the information provided in the data forms and they 
were encouraged to complete them as much as possible.  
 
2.8.1 Participating centres in the pilot study 
	















Regional organ donation services 
 
1 Scottish region 




2.8.2 Findings of the pilot study and subsequent amendments 
 
The number of completed forms was compared with the NHSBT data on the total 
number of transplants that were undertaken within that period for each centre. The 
level of participation of each centre was thus assessed.  Each form was also 
scrutinised for completeness of the data provided. 
 
Feedback relating to the data forms was examined and pared down to simplify them 




Initially, 4 separate sets of questionnaires, one for each team of SN-ODs, H&I staff, 
transport personnel and recipient coordinators/transplanting surgeons were designed 
to encapsulate critical events along the kidney timeline. We studied the data 
available from ODT. The data already collected by ODT were removed from the 
proforma to avoid unnecessary duplication of effort. Effort was made to ensure that 
the proformas were simple and comprehensive.  
 
As most of the information around the process of organ donation at donor hospital 
was already available from ODT data collection form it was decided that two more 
data points required for the study should be added to the form thus removing the 
necessity for a separate SN-OD form. It was also agreed that additional data relevant 
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to the study on transplants and transport would be provided on a monthly basis by 
ODT. 
 
Finally, data collection for each DD kidney donation and transplant were narrowed 
down to 3 separate sources, which were then amalgamated to provide a complete 
picture encompassing the whole kidney journey.  
 
The 3 principal sources for data collection were –  
 
• ODT – provided data on monthly national transplant activities, donor 
activities and 3 monthly data on transport for transplant (TFT).  
• H&I forms – provided data on activities around crossmatch 
• Recipient forms – provided data on activities around recipient 
preparation and transplantation. 
 
The data collection forms were ratified by the steering group, with final approval 
from the supervisors. The questionnaires were then rolled out and distributed to all 
participating centres. These were returned to the principal investigator after 








2.10 Dissemination of study information 
 
Newsletters were also distributed to all centres to provide an update on their hard 
work and insight into their own performance. Leaflets with information on the study 
were also distributed at the Annual British Transplantation Society Conference to 
raise awareness of the study. (Appendices 8, 9) 
 
2.11 Multicentre engagement 
 
2.11.1 Centre visits 
 
Over a one-year period, 21 transplant units, 19 H&I units and 2 Donor Transplant 
Coordinator teams in the UK were individually visited in preparation for 
participation in the study. The aim of the visits was to introduce the study and to 
encourage full participation. 
 
The head of each unit was first contacted via email to inform them about the study 
and to request to arrange a meeting with as many of their staff members as possible. 
To ensure the presence of maximum number of staff and for minimum disruption to 
their work, slots were requested to fit into one of their own monthly meetings where 
possible. Also, efforts were made to arrange visits to both the transplant units and 
their supporting regional H&I units on the same day. An overview of the study was 
presented to each team and was discussed with individuals who would require to 
complete the forms at each stage of the kidney journey, including SN-ODs, recipient 
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coordinators (RCs), transplant surgeons, specialty registrars (SpRs), clinical fellows, 
nephrologists, clinical scientists and staff at tissue typing laboratories.  
	
2.11.2 Kidney transplant centres 
	
21 out of the 22 kidney transplants units in the UK were visited. One agreed to 
participate in the study without a visit. Belfast City Hospital was not included. 16 out 
of the 22 invited transplant centres signed up to the study.   
• Birmingham Queen Elizabeth Hospital 
• Bristol Southmead Hospital 
• Cambridge Addenbrooke’s Hospital 
• Coventry University Hospital 
• Edinburgh Royal Infirmary 
• Glasgow Western Infirmary 
• Leicester General Hospital 
• London – Guy’s Hospital and Great Ormond Street Hospital 
• London – St George’s Hospital 
• London – Royal Free Hospital 
• London – West London Renal and Transplant Centre 
• Nottingham City Hospital 
• Oxford Churchill Hospital 
• Plymouth Derriford Hospital 
• Portsmouth Queen Alexandra Hospital 
• Sheffield Northern General Hospital 
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2.11.3 Histocompatibility and Immunogenetics units  
	
19 H&I units supporting all 22 transplant centres were visited and all signed up to 
the study.  
• Birmingham NHSBT  
• Bristol Southmead Hospital 
• Cambridge Addenbrooke’s Hospital 
• Edinburgh SNBTS  
• Glasgow Gartnaval Hospital 
• Leeds St James’s University Hospital 
• Leicester General Hospital 
• Liverpool Royal Liverpool University Hospital 
• London – Guy’s Hospital 
• London – Royal Free Hospital 
• London – Hammersmith Hospital 
• London – Tooting 
• Manchester Royal Infirmary 
• Newcastle NHSBT 
• Northern Ireland Blood Transfusion Service  
• Oxford Churchill Hospital 
• Plymouth Derriford Hospital 
• Sheffield NHSBT 
• Wales Welsh Blood Service 
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2.11.4 Regional donor transplant coordinator teams  
	
It was agreed that relevant donor data would be included in the NHSBT form already 
used by all 12 regional donor transplant coordinator teams.  
 
• Eastern Region Cambridge 
• London Region London 
• Midlands Region Birmingham 
• Northern Ireland Region Belfast 
• North West Region Liverpool 
• Northern Region Newcastle 
• Scotland Region Falkirk 
• South Central Region Oxford 
• South East Region West Sussex 
• South Wales Region Cardiff 
• South West Region Exeter 









2.12 Deceased donor kidney transplant logistics 
 
Visits to transplant centres across the country provided a unique insight into variation 
in local practices and procedures and revealed complex and multifactorial nature of 
the logistics of DD kidney transplant in the UK.  
 
There were variations relating to structure and modus operandi of a number of 
transplant centres, H&I units and transport providers.  
 
2.12.1 Transplant centres 
 
In Liverpool transplant unit, SpRs take the calls instead of the RCs whereas in 
Leicester, the Professor takes the calls and SpRs prepare recipients. RCs are only 
available during normal working hours in Liverpool and Leeds. In Glasgow, 
consultant transplant surgeons take the calls and SpRs out of hours. There are no 
RCs at Royal London, Guy’s or Royal Free transplant units. Transplant surgeons 
coordinate transplants at the Royal London. At the Royal Free nephrologists, 
transplant surgeons or clinical fellows take calls. Urologists may also be involved out 
of hours and, kidneys are delivered in theatre rather than on the ward. In 
Birmingham, RCs coordinate transplants but are not involved in theatre. In Plymouth 
and Sheffield, RCs work from home full time and in Newcastle, RCs take call out of 
hours from home. Coventry transplant unit is unique in that all DD transplants are 




2.12.2 Histocompatibility and Immunogenetics units and virtual 
crossmatch policy 
 
Each H&I unit usually supports its regional transplant unit. Exceptions to this are 
Guy’s H&I laboratory which supports 3 regional transplant units, namely, Guy’s, St 
George’s and Great Ormond Street Hospital (GOSH); St George’s H&I laboratory 
(Tooting) supports St George’s and Portsmouth transplant units; Sheffield H&I 
laboratory supports Sheffield and Nottingham transplant units; and Birmingham H&I 
laboratory supports Birmingham and Coventry transplant units.  
	
Two out of the 19 H&I units did not practise vXM policy which were the regional 
H&I laboratories for Hammersmith and for Newcastle transplant units. In Liverpool, 
list of recipients suitable for vXM was available to transplant surgeons who make the 
decisions for suitable transplants with a vXM without the need for confirmation with 
the Consultant Clinical Scientist. H&I laboratories always performed retrospective 










2.12.3 Transport  
 
The majority of transport facilities for transport of donated organs for transplant and 
blood and tissues for typing and crossmatching were provided centrally by Transport 
for Transplant (TFT) based in Birmingham. Liverpool, however, had their own local 
transport facilities for organs, bloods and tissues and were not involved with TFT. 
 
2.13 Variation in local transplant centre practices  
	
An additional study to assess robustness of the support system in centres undertaking 
deceased donor (DD) kidney transplant was done while visiting all transplant centres. 
Information was collected with a view to identifying areas for improvement at local 
level that may help to achieve better transplant outcomes.  
 
A supplementary questionnaire was designed to gain insight into any local variations 
in the current practices in UK transplant centres involved in DD kidney 
transplantation. During transplant centre visits, the lead or senior transplant surgeon 
in each transplant unit completed the questionnaire. 
 
This observational study included data collected from 22 transplant centres. 
Information on other organs transplanted in the unit, access to theatre including 
options for simultaneous DD transplant for 2 kidneys if required and whether they 
would cancel an elective kidney transplant for a DD kidney transplant, number of 
consultant transplant surgeons actively involved in DD kidney transplant, local 
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allocation policy, availability of a dedicated anaesthetic team, availability of theatre 
staff, number of dedicated ICU, HDU and ward beds available for DD kidney 
transplants, and other factors affecting ability to take the patient to theatre for 
transplant were recorded. (Appendix 7) 
 
The data on variation in local practices included factors relating to the following – 
 
1. Multi-organ or Kidney only transplant centre 
2. Manpower availability 
3. Consultant transplant surgeons 
4. Dedicated anaesthetic team  
5. Theatre staff  
6. Theatre availability 
7. Theatre accessibility 
8. Theatre practice 
9. Local allocation policy for DCD kidneys 
10. Access to H&I services 
11. Recipient factors 








Two principal scenarios for kidney timeline were identified. (Figures 2.2 and 2.3) 
Figure 2.2 Transplants with pXM 
 
	

















































































2.14 Crossmatching Description 
 
Several centres in the United Kingdom have adopted selective omission of the pre-
transplant crossmatching in potential recipients who are at low immunological risk, 
and this has been shown to be safe and effective at reducing CIT.  
For clarification in this study the term pre-transplant crossmatching (pXM) is used 
for those transplants that required full crossmatch (XM) testing to be performed 
before start of surgery, and virtual crossmatch (vXM) for those in whom the 
prospective pre-transplant donor XM was omitted and it was safe to proceed without 
waiting for the XM test to be performed. The formal XM test was performed 















2.15 Data Collection 
 
Data were obtained on DD kidney only and simultaneous pancreas and kidney (SPK) 
transplants from the 16 transplant centres along with the 19 H&I laboratories, with 
the aim of determining whether there are specific areas on which to focus efforts to 
reduce CITs.  All data were collected prospectively. At the end of each month of the 
study period, this was checked against the ODT data on transplantation for each 
centre. Every form was chased with emails sent out to each centre with a list of any 
outstanding forms to ensure full engagement as well as to encourage them to 
complete and return as many forms as possible.  
 
The CIT was calculated from United Kingdom Transplant Registry data held by 
NHSBT. It was defined as the time from in situ cold perfusion in donor at the time of 
retrieval to the time of removal of kidney from ice for transplantation in recipient. 
This was available for all transplants performed in all 22 centres.  
 
Factors that were considered to be relevant for this study were agreed with a national 
multidisciplinary team, including transplant surgeons, H&I scientists, and 
statisticians. In addition, draft documents were circulated to the heads of transplant 
centres for their input.  
 
Categorical and continuous data were collected along the kidney timeline from the 
time of organ donation at the donor hospital to completion of transplantation at 
recipient hospital on 4 different data collection forms, focusing on five key logistical 
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areas, namely, donor operation, organ transport, laboratory tests, recipient 
preparation and theatre. Different factors within each of these key areas were 
examined to identify those that impacted on CIT.  
 
2.16 Data Input 
 
A national database was set up and up to date data input was done prospectively. 
Data were checked for errors with frequency analyses and diagrams.  Each outlier 
was examined by re-checking them against the original forms as well as with the rest 
of the data for the corresponding transplant. We excluded transplants that did not 
proceed despite retrieval of organs and the kidneys that were transplanted with 
organs other than pancreas. When two kidneys were transplanted in a single recipient 
(dual kidney transplant) the one with the longer CIT was excluded. Data on recipient 
and theatre times that were inconsistent with the rest of the data and those that had a 
discrepancy of more than 1 hour from NHSBT data were excluded (n=52 
transplants).  Transplants with no virtual cross-match (vXM) or prospective pre-









2.17 Data Cleansing and Quality Assurance 
 
Data cleansing was undertaken before the final analysis: 5% of the data were 
selected randomly at regular intervals, and each one was checked against the original 
forms and records to establish excellent quality assurance of the input data. An error 
rate less than 1% was considered acceptable. All time intervals were recalculated and 
corrected following data cleansing to maintain accuracy. 
 
Information was available for all donors and crossmatch types, 37% of transports, 
32% of recipients, and 35% of theatre activities, with varying levels of completeness 
of data for each activity.. 
 
2.18 Statistical Analysis 
 
All data for DD kidney and SPK transplantation were calculated for general 
demographics including number and type of donor, type of allocation, reallocation, 
crossmatching, transport of kidneys, recipient, theatre and kidney transplants were 
calculated. Various categorical factors and time intervals contributing to the total 
CIT were determined using univariate analysis using general linear model. The time 
intervals in the univariate analysis were calculated in hours. Several time intervals 
between process of donation and completion of transplantation were examined. 
These were times around the donation activities, retrieval surgery, organ transport, 
tissue typing and crossmatching, recipient preparation and theatre. Various 
categorical data were included in the analysis for donor, namely,donor type and 
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donor tissues used for pre-transplant crossmatching (pXM). Categorical data 
included for transport were mode of kidney transport and those included for H&I 
activities were type of crossmatch, types of donor tissues and recipient serum 
samples used for pXM. The categorical data for recipient included mode of recipient 
travel, requirement for haemodialysis immediately pre- transplant and requirement 
for current recipient serum sample for pXM.  The categorical data included for 
theatre activities was type of theatre where transplant was performed.  For each 
categorical and continuous variable, parametric tests with log transformation of CIT 
as the dependent variable were performed to assess their contribution to CIT. 
ANOVA test was used to perform univariate comparisons of transplants from DBD 
versus DCD donors and for transplants performed with a virtual crossmatch (vXM) 
versus pXM for all the categorical and continuous data. P-values of <0.05 were 
considered significant. All univariate analyses were done with SPSS version 21.  
 
Those categorical and continuous factors in pXM and vXM groups that were found 
to be significant in the univariate analyses were included in the multivariate model. 
The multivariate analysis included 97% of the data included in the univariate 
analyses as only transplants with complete data for CIT and type of crossmatch 
performed were included. The multivariate analyses were carried out by NHSBT 
statisticians using SAS. 
 
 
2.19 Intercept Description 







A total of 1763 transplants from 1037 donors performed within the 14-month study 
period were included. Of those, 41% were DCD and 59% DBD transplants. While 
the majority of the transplants were kidney-only transplants (90%), 10% were 
simultaneous pancreas and kidney (SPK) transplants. Kidney-only transplants 
included 59 pairs of double and en-bloc kidneys; the rest were single kidney 
transplants. Two recipients were transplanted twice within the study period.  
 
The majority of kidneys (64.5%) were shipped from a different region (imports) and 
35.5% were allocated either locally or regionally. Whereas DBD kidneys made up 
for the majority of imports (78.4%), most of the DCD kidneys were transplanted 
locally or regionally (76.8%).  A small number of kidneys (2.4%) were reallocated, 



















DBD  1036 (59) 




Kidney-only / SPK 
transplants 
Kidney-only 
Single kidney transplant 1527 
(90) Double kidney transplant 
(including 4 En-bloc) 
59 
pairs 
SPK 177 (10) 
Dual/En-bloc kidney 
transplants 
DBD  7 
pairs 
(11.9) 




DBD  619 (59.7) 





1 transplant within study period 1759  
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No 1720 (97.6) 
Yes 
Total 43 (2.4) 
Local 
Once 29 (67.4) of 
reallocation 
Twice 3 (7.0) of 
reallocation 




3.2 Review of current practices in UK transplant centres 
	
There was an average of 4 Consultant Transplant Surgeons in each kidney-only 
transplant centre and 6 in multi-organ transplant centres. 14 of the 22 centres had no 
dedicated anaesthetic team for deceased donor (DD) kidney transplants. Five centres 
had a dedicated anaesthetic team for day-time activity and one centre for out of hours 
transplants only. There was a dedicated anaesthetic team for DD kidney transplants 
both in and out of hours in only 2 centres; both of these centres are multi-organ 
transplant centres.  
 
Six transplant centres would cancel an elective transplant in favour of a DD kidney 
transplant. Nine transplant centres had no facilities for simultaneous transplantation 
of two DD kidneys if it was required. Only 2 out of the 22 transplant centres have 
round the clock access to a dedicated transplant theatre while 15 centres have access 












Table 3.2 Logistical variations in local transplant centre practices 







Dedicated anaesthetic team 
available for kidney 
transplant? 
No 8 6 14 
In-hours only 2 3 5 
Both in and out of 
hours 0 2 2 
Out of hours only 1 0 1 
Would you cancel elective 
transplant for a DD kidney 
transplant? 
No 7 8 15 
Yes 3 3 6 
Not known 1 0 1 
Options for doing 
simultaneous kidney 
transplant for two DD 
kidneys if required 
No 8 1 9 
In-hours only 1 8 9 
Both in and out of 
hours 1 1 2 
Rarely 1 1 2 
Access to theatre for DD 
kidney transplant. 
Dedicated transplant 
theatre but in-hours 
only 
1 4 5 
Dedicated transplant 
theatre both in and out 
of hours 
1 1 2 
Access to emergency 













3.3 Cold ischaemia time 
	
The number of transplants with known cold ischaemia time (CIT) was 1591 out of 
the 1763. The overall median CIT for kidney transplants in all transplant centres was 
13.4 hours (SD 4.5, Interquartile range (IQR) 10.7-16.4). The shortest recorded CIT 
was 3.7 hours, and the longest was 33.1 hours. (Table 3.3, Figure 3.1) 
Table 3.3 Overall CIT 
Overall CIT in hours 
Mean SD Minimum Maximum Median (IQR) 
13.8 4.5 3.7 33.1 13.4 (10.7-164) 
 
	




The difference in CIT between simultaneous pancreas and kidney (SPK) transplants 
and kidney alone transplants was not statistically significant (12.9 hours and 13.5 
hours, respectively). (F=0.959, p=0.328) 
	
	
3.3.1 Cold ischaemic time by transplant centre 
 
There was significant centre variation in mean CIT across the 22 UK transplant 
centres ranging from between 11.5 hours and 19.2 hours (F=10.193, p<0.0005). 
Edinburgh had the shortest median CIT at 10.8 hours and Hammersmith the longest 
at 18.1 hours.  (Table 3.4, Figure 3.2)  
 





Table 3.4 Cold ischaemia time in UK transplant centres in hours (p<0.0001) 
Recipient transplant 
centre 
n Mean  SD Minimum  Maximum  
Median (IQ 
Range) 
Cambridge 128 14.1 4.0 5.2 25.8 13.6 (11.5-16.7) 
Oxford 147 13.0 3.7 5.9 28.2 12.5 (10.4-14.9) 
Nottingham 85 13.8 4.1 5.5 24.2 14.2 (11.5-15.9) 
Plymouth 26 15.1 4.6 7.6 29.4 14.6 (11.7-17.1) 
Newcastle 43 17.5 4.3 9.3 31.3 16.6 (14.6-20.4) 
Guy’s 110 12.2 4.0 5.2 23.6 11.7 (9.7-14.3) 
Hammersmith 40 19.2 5.3 8.8 31.2 18.1 (15.0-23.4) 
Leicester 39 12.2 5.2 5.7 29.0 10.7 (8.1-16.5) 
Manchester 159 14.4 4.4 5.4 28.9 13.9 (11.4-17.4) 
Sheffield 39 15.1 4.8 5.6 33.1 15.2 (12.9-17.0) 
Portsmouth 43 15.0 3.6 5.1 22.0 15.2 (13.1-18.0) 
Birmingham 29 16.7 6.6 7.8 29.6 14.0 (11.4-22.8) 
Edinburgh 77 11.5 4.0 4.1 24.4 10.8 (8.5-13.9) 
Liverpool 80 14.8 4.7 5.9 29.1 14.9 (11.6-17.6) 
Bristol 51 14.0 2.7 7.7 21.3 13.9 (12.6-15.4) 
St George’s 51 11.8 3.6 4.0 20.1 11.7 (9.1-14.3) 
Leeds 96 14.4 4.1 6.9 30.3 13.9 (11.8-16.2) 
The Royal Free 81 12.4 3.4 5.9 23.1 12.0 (10.1-14.1) 
The Royal London 54 13.2 4.6 4.7 25.4 12.6 (9.4-15.7) 
Coventry 13 16.0 6.2 8.2 28.9 14.7 (11.0-21.4) 
Cardiff 99 13.1 4.2 5.9 25.3 12.4 (10.0-16.3) 
Glasgow 101 12.7 4.5 3.7 23.5 13.1 (8.6-16.0) 
Total 1591      
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3.3.2 Cold ischaemic time in kidney-only and multi-organ transplant 
centres 
 
Half of the 22 UK transplants units perform deceased donor (DD) kidney-only 
transplants and the other half, the multi-organ transplant centres, also transplant other 
organs such as pancreas and / or liver and / or small bowel in addition to kidneys. 
Comparison of CIT between kidney-only and multi-organ transplant centres did not 
show any significant difference (Mean 13.7 and 13.8, respectively, p=0.512). (Table 
3.5, Figure 3.3)  
	
Table 3.5 Cold ischaemia time in kidney only and multiorgan transplant centres 
Transplant Centres n 
CIT in hours 
Mean  SD Minimum  Maximum  Median (IQ Range) 
Kidney-only 582 13.7 4.4 3.72 33.1 13.9 (10.6-16.5) 



























3.3.3 Cold ischaemic time in relation to kidney allocation 
(Local/Import) 
 
Mean CIT for kidney transplants that were performed with kidneys imported from a 
different region (64.5%) was significantly higher than for those that were 
transplanted locally or regionally (35.5%) (p<0.0005). (Table 3.6, Figure 3.4) 
 
The majority of locally transplanted kidneys were DCD kidneys and 78% of 
imported kidneys were DBD kidneys.  
 
Table 3.6 Cold ischaemia time for local/regional and imported kidney 
transplants 
Allocation n 
CIT in hours 
Mean  SD Minimum  Maximum  Median (IQ Range) 
Local 525 12.8 4.4 3.7 29.1 12.4 (9.6-15.9) 
Import 1066 14.2 4.5 5.0 33.1 13.9 (11.1-16.6) 
 























3.3.4 Cold ischaemic time in relation to reallocation of kidneys 
 
The number of reallocated kidneys was small (n=40). Reallocation of kidneys 
following their initial acceptance added 3.5 hours to median CIT (p<0.0005). (Table 
3.7, Figure 3.5).  
 
Table 3.7 Cold ischaemia time for reallocated kidney transplants 
Reallocated kidneys n 
CIT in hours 
Mean  SD Minimum  Maximum  Median (IQ Range) 
No 1551 13.7 4.5 3.7 33.1 13.3 (10.6-16.3) 
Yes 40 17.9 4.1 12.1 29.4 16.8 (14.7-20.9) 
 





























The median CIT for kidneys that were reallocated from a different transplant centre 
was significantly longer (6 hours) than for those that were reallocated a single time 
locally (3 hours) (p<0.0005). (Table 3.8, Figure 3.6) 
	




CIT in hours 
Mean  SD Minimum  Maximum  
Median (IQ 
Range) 
No 1551 13.7 4.5 3.7 33.1 13.3 (10.6-16.3) 
Locally once 26 17.1 3.9 12.0 29.4 16.5 (14.4-19.6) 
Locally twice 3 17.4 4.1 12.9 21.0 18.3 (-) 
From other centre 11 19.9 4.2 13.7 26.4 19.6 (16.6-22.9) 
 




























3.4 Donor factors and impact on cold ischaemia time 
 
All donor data for activities around the donation process were available. There were 
1037 deceased donors from whom 1763 kidneys were transplanted including 59 pairs 
of double and en-bloc kidneys, in a total of 1761 recipients (twice in 2 recipients). 
DBD and DCD donors constituted 59.7% and 40.3% of the total, respectively.  
 
3.4.1 Type of donor  
	
The median CIT for transplants with kidneys from DCD donors was significantly 
shorter than that for transplants with kidneys from DBD donors (12.7 hours and 13.8 
hours, respectively) (p<0.0005) with some DBD kidneys being transplanted beyond 
30 hours of CIT. (Table 3.9, Figure 3.7) 
 
Table 3.9 Cold ischaemia time for DBD and DCD donor kidney transplants 
Donor n 
CIT in hours 
Mean  SD Minimum  Maximum  Median (IQ Range) 
DBD 987 14.2 4.6 3.7 33.1 13.8  (11.0-16.7) 
DCD 604 13.0 4.2 4.1 25.9 12.7 (10.0-15.7) 
 




















3.4.2 Centre variation in cold ischaemia time  
 
The number of transplants ranged between 13 in Coventry and 159 in Manchester. 
Whilst Leicester did not perform any DCD transplants, it ranged between 12% in 
Hammersmith and 78% in Plymouth. (Table 3.10) 
 
There was also significant variation in CIT between DBD and DCD kidney 
transplants within transplant centres (p<0.0005) with the largest difference seen in 
Glasgow where CIT was 6 hours shorter for DCD transplants. (Table 3.10, Figures 
























n Mean SD Median (IQR) n Mean SD 
Median 
(IQR) 
Cambridge 39 14.4 4.1 13.6 (11.4-16.9) 100     14.1 4.0 13.6 (11.5-16.8) 
Oxford 104 12.9 3.8 12.3 (10.4-14.3) 52 13.3 3.6 13.5 (11.0-15.2) 
Nottingham 52 15.0 3.3 14.7 (13.1-16.9) 36 11.8 4.4 11.5 (7.6-15.1) 
Plymouth 8 18.7 5.5 16.9 (14.5-22.3) 29 13.8 3.5 14.0 (10.9-15.5) 
Newcastle 21 16.8 4.8 16.5 (14.1-18.2) 45 18.2 3.9 17.7 (15.2-20.7) 
Guy’s 89 12.6 4.1 11.9 (10.7-14.4) 45 11.4 3.7 11.4 (8.0-14.2) 
Hammersmith 52 19.6 5.4 18.8 (15.2-24.2) 7 15.8 3.3 16.8 (13.7-18.0) 
Leicester 40 12.2 5.2 10.7 (8.1-16.5) 0 - - - 
Manchester 116 14.7 4.4 14.0 (11.7-17.4) 50 13.9 4.4 13.4 (10.7-17.2) 
Sheffield 26 15.8 4.7 15.4 (13.4-16.6) 15 13.7 4.9 13.5 (12.2-17.0) 
Portsmouth 37 15.1 3.4 15.1 (13.2-18.0) 11 14.1 4.7 16.7 (10.7-17.1) 
Birmingham 22 17.6 7.0 15.3 (12.3-23.8) 8 14.1 5.1 12.5 (9.9-18.6) 
Edinburgh 58 12.4 3.9 11.2 (9.3-15.6) 23 8.9 3.1 7.2 (6.6-11.6) 
Liverpool 43 16.4 4.8 16.5 (14.0-18.5) 43 13.0 4.0 12.4 (10.8-16.2) 
Bristol 31 13.6 2.8 13.7 (11.5-14.8) 22 14.6 2.5 14.2 (13.3-16.0) 
St George’s 
 41 11.9 3.6 11.6 (9.1-14.8) 17 11.4 3.6 12.5 (9.5-13.2) 
Leeds 57 14.7 4.6 14.0 (12.0-16.2) 57 13.9 3.3 13.9 (11.6-16.2) 
The Royal 
Free 46 13.1 3.9 13.1 (10.6-15.7) 36 11.5 2.2 11.5 (9.9-12.6) 
The Royal 
London 32 14.2 5.1 14.0 (9.8-17.4) 28 11.7 3.4 11.0 (9.0-13.9) 
Coventry 11 16.8 6.3 14.8 (11.3-22.3) 2 11.5 4.6 11.5 (8.2-14.7) 
Cardiff 39 13.6 3.7 12.8 (10.8-16.0) 70 12.7 4.5 11.9 (9.2-16.3) 





Figure 3.8 Mean cold ischaemia time for DBD and DCD donor kidney 












Figure 3.9 Median cold ischaemia time for DBD and DCD donor kidney 











3.4.3 Timing of dispatch of donor blood for tissue typing in relation to 
duty office notification of potential donor 
 
Once a donor is identified, donor pre-retrieval peripheral blood is dispatched to H&I 
laboratory for tissue typing (TT). There was wide variation in the time interval 
between dispatching of the donor blood and notification of donor to duty office 
(donor notification) for both DBD and DCD donors. In the case of DBD donors, the 
timing of donor notification ranged from 47.5 hours before dispatching of donor 
blood for TT to 26.1 hours after. For DCD donors, it ranged from 57.5 hours before 
dispatching of donor blood for TT to 18.0 hours after.  
 
3.4.4 Donor HLA typing time 
 
The mean time interval between donor blood sample dispatched for tissue typing 
(TT) and HLA data received by Duty Office (DO) (TT time) was 6.8 hours (SD 4.0).  
 
3.4.5 Timing of retrieval surgery  
 
There was a significant difference between the timing of retrieval surgery in relation 
to completion of the match run between DBD and DCD donors (F=179.886, 
p<0.0001). On average, retrieval surgery started 5.7 hours (SD 3.9) after the match 
run was completed for DBD donors and 2.0 hours (SD 4.2) after for DCD donors. In 
both groups, some retrieval operations started before the match runs were completed; 
27 DBDs and 124 DCDs retrievals started before match run was completed.  
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3.4.6 Timing of start of retrieval surgery (knife to skin) and kidney in 
ice box 
The interval between knife to skin and kidney in the ice box was a mean of 1.31 
hours (SD 0.46) with the minimum interval of 0.18 hours (11 minutes) and the 
maximum of 3.68 hours (221 minutes). There was no significant difference in the 
time interval for DBD and DCD donors (Mean 1.31 hours and 1.29 hours, SD 0.43 
and 0.49, respectively) (F=1.218, p=0.270) 
 
3.4.7 Timing of kidney offer in relation to retrieval surgery 
 
There was a significant difference in the timing of offer for DBD and DCD kidneys 
(F=11.826, p=0.001), with a large proportion of DCD kidneys being offered before 
the start of retrieval (72.1% vs 55.4%) but the impact of donor type on CIT in the 


















Figure 3.10 Timing of kidney offer in relation to start of retrieval surgery in 














Figure 3.11 DBD and DCD kidney offer in relation to start of transplantation 









Timing of offer significantly impacted on CIT, with organs that were offered at or 
before start of retrieval surgery having shorter CIT as compared to those offered after 
start of retrieval surgery. There was more than 2 hours’ difference in CIT between 
the two groups (p<0.0001). (Table 3.11, Figure 3.12)  
 
The timing of offer was significant for DBD kidneys (F=25.024, p=0.0001) but not 
for.DCD kidneys (F=3.200, p=0.076) (Figure 3.13) 
 
Table 3.11 Timing of kidney offer and impact on cold ischaemia time 
Timing of offer n 
CIT in hours 
Mean  SD Minimum  Maximum  Median (IQ Range) 
Before knife to skin 247 11.3 3.9 3.7 24.4 10.7 (8.6-13.3) 
After knife to skin 147 13.7 5.0 5.2 29.4 12.9 (9.9-16.5) 
 
































Figure 3.13 Impact of timing of DBD and DCD kidney offer in relation to 







3.4.8 Timing of kidney in ice box in relation to in situ cold perfusion at 
retrieval surgery  
 
The data were available for 686 kidneys. The median time interval was 1.3 hours 
(IQR 1.0-1.6). (Figure 3.14) 
 








3.4.9 Timing of kidney collection in relation to kidney put in ice box  
	
The data were available for only 320 kidneys. Median time interval between kidney 
put in ice box and kidney collected for transport was 1.0 hour (IQR 0.7-1.3). (Figure 
3.15) 
 








3.5 Transport Factors and impact on cold ischaemia time 
 
Sixty-seven percent of the kidneys for transplant were imported from a different 
centre, thus requiring use of transport facilities to ship kidneys. Transport data were 
available for all 1137 imported kidneys.  
 
3.5.1 Kidney travel distance 
 
Kidneys for transplants were grouped into 6 categories according to the distance 
travelled from donor hospital to recipient transplant centre which was calculated as 
the straight line between the centres using GoogleMaps. 
 
 Group 1: In-house 
 Group 2: Under 20 miles 
 Group 3: 20-50 miles 
 Group 4: 50-100 miles 
 Group 5: 100-200 miles 
 Group 6: Over 200 miles 
 
There was a wide variation in distance travelled by retrieved kidneys from 122 donor 












Figure 3.16 Number of transplants in relation to distance between donor 









There was a positive correlation between the groups of distance travelled by kidneys 
and their CIT; this was significant when the distance was above 100 miles. (Figure 
3.17) 
 
Figure 3.17 Impact of travel distance between donor hospital and recipient 
transplant centre on cold ischaemia time 
 
 







3.5.2 Variation in travel time and distance for DBD and DCD kidneys 
 
The data for kidney collection and delivery time (kidney travel time) were available 
for 67% of imported kidneys. It took an average of an hour for kidneys to be 
collected by transport personnel after they were put in ice box. Distance travelled by 
DBD kidneys was considerably longer (median 95.9 miles) with longer travel time 
(median 2.5 hours) than DCD kidneys (median 23.5 miles and median 1.3 hours, 







































Figure 3.19 Distance between donor hospital and recipient transplant centre for 











3.5.3 Mode of transport of kidneys  
 
The data for mode of transport for imported kidneys were available for 544 kidneys 
(48%). The kidneys were grouped according to their mode of transport of as follows:  
 Road 
 Road and blue-lighted 
 Road and air 
 Road and ferry 
 
Majority (420) of kidneys travelled by road, 65 were transported by road and blue 
lighted, 57 by air and 2 by ferry. (Figure 3.20) 
 
Of the 4 categories of transport kidneys transported by air travelled the furthest 
distance (median 299.5 miles) and had the longest travel time (median 4.1 hours). 






























Figure 3.21 Distance travelled by kidneys and the mode of transport 
 
 

























However, CIT for kidneys transported by air were not significantly different than for 















3.6 H&I factors and impact on cold ischaemia time 
 
3.6.1 Crossmatching  
 
The majority of the transplants were performed following a prospective pre-
transplant crossmatching (pXM) to establish HLA compatibility between donor and 
recipient (63.9%). A third of the transplants were performed with a virtual 




Table 3.12 Number transplants with pre-transplant crossmatch (pXM) and 
virtual crossmatch (vXM) 
XM  n (%) 
pXM 1127 (63.9) 
vXM 636 (36.1) 











There was a significant difference in CIT between the pXM and vXM groups, which 
approached 3 hours (F=204.066, p<0.0001). (Table 3.13, Figure 3.24) 
 
Table 3.13 Impact of type of crossmatch on cold ischaemia time 
XM 
CIT (hours) 
Mean (SD) Median (IQR) 
pXM 14.8 (4.2) 14.3 (12.0-17.0) 
vXM 12.0 (4.4) 11.4 (8.8-14.4) 
 








The majority of both DBD and DCD kidney transplants was performed following 
pXM, although a higher proportion of DCD kidney transplants was performed with a 













3.6.2 Type of crossmatching for DBD and DCD kidney transplants 
 
CIT was significantly shorter when transplants proceeded with a vXM for both DBD 
and DCD transplants than when they required a pXM. Median CIT was 3.0 hours 
and 2.8 hours shorter for DBD and DCD transplants, respectively, for vXM group. 
(Table 3.14, Figures 3.26, 3.27) 
 
 




Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
 pXM 15.2(4.4) 14.6 (12.3-17.3) 14.1 (3.8) 14.0 (11.6-16.5) 















































3.6.3 H&I laboratory variation in type of crossmatching  
	
There was a wide variation in crossmatching policy across the H&I laboratories.  
Two of the laboratories, Hammersmith and Newcastle, did not have a vXM policy. 
Leicester performed 99% of their transplants with a vXM. (Figure 3.28, Table 3.15) 
 
 








Table 3.15 H&I laboratory variation in crossmatching policy 
H&I Laboratory pXM (%) vXM (%) Total  
Birmingham 22 (51.2) 21 (48.8) 43 
Bristol 46 (86.8) 7 (13.2)  53 
Cambridge 56 (40.3) 83 (59.7) 139 
Cardiff 90 (82.6) 19 (17.4) 109 
Edinburgh 15 (18.5) 66 (81.5) 81 
Glasgow 50 (48.5) 53 (51.5) 103 
Guy’s, London 122 (77.2) 36 (22.8) 158 
Hammersmith, London 59 (100) 0 59 
Leeds 71 (63.4) 41 (36.6) 112 
Leicester 1 (2.5) 39 (97.5) 40 
Liverpool 42 (48.8) 44 (51.2) 86 
Manchester 89 (53.6) 77 (46.4) 166 
Newcastle 66 (100) 0 66 
Oxford 129 (82.7) 27 (17.3) 156 
Plymouth 19 (51.4) 18 (48.6) 37 
Royal Free, London 69 (82.1) 15 (17.9) 84 
Royal London, London 26 (43.3) 34 (56.7) 60 
Sheffield 102 (79.1) 27 (20.9) 129 










There was a significant difference in median CIT between pXM and vXM 
transplants for each H&I laboratory. All kidney transplants that proceeded with a 
vXM had a shorter median CIT in each H&I laboratory. (Figure 3.29, Table 3.16) 
 
 









Table 3.16 Cold ischaemia time for kidney transplants with pXM and vXM in 
each H&I laboratory 




Mean (SD) 18.5 (6.1) 14.4 (6.2) 
Median (IQR) 17.3 (12.9-23.4) 13.3(9.7-16.1) 
Bristol 
Mean (SD) 14.3 (2.5) 11.4 (2.6) 
Median (IQR) 13.9 (13.1-15.9) 11.3 (8.9-14.0) 
Cambridge 
Mean (SD) 14.8 (3.2) 13.7 (4.4) 
Median (IQR) 14.8 (12.8-16.6) 13.0 (11.2-16.9) 
Cardiff 
Mean (SD) 13.2 (4.2) 12.3 (4.6) 
Median (IQR) 12.7 (10.1-16.3) 10.5 (9.1-15.8) 
Edinburgh 
Mean (SD) 13.0 (4.4) 11.2 (3.9) 
Median (IQR) 12.7 (9.1-17.8) 10.3 (8.5-13.2) 
Glasgow 
Mean (SD) 15.7 (3.0) 9.9 (3.7) 
Median (IQR) 15.3 (14.3-17.2) 8.7 (7.0-12.2) 
Guy’s, London 
Mean (SD) 12.3 (3.5) 11.5 (4.8) 
Median (IQR) 11.8 (10.4-14.3) 10.2 (8.8-13.9) 
Hammersmith, London 
Mean (SD) 19.2 (5.3) - 
Median (IQR) 18.1 (15.2-23.3) - 
Leeds 
Mean (SD) 15.6 (4.0) 12.1 (3.5) 
Median (IQR) 14.9 (13.1-17.0) 11.2 (9.5-13.9) 
Leicester 
Mean (SD) 14.1 (-) 12.1 (5.3) 
Median (IQR) 14.1 (14.1-14.1) 10.7 (8.1-16.5) 
Liverpool 
Mean (SD) 16.4 (4.4) 13.1 (4.5) 
Median (IQR) 16.5 (14.0-18.9) 12.8 (10.8-16.2) 
Manchester 
Mean (SD) 16.3 (3.8) 12.3 (4.2) 
Median (IQR) 16.1 (13.6-18.2) 11.7 (9.3-14.5) 
Newcastle 
Mean (SD) 17.5 (4.4) - 
Median (IQR) 16.6 (14.6-20.4) - 
Oxford 
Mean (SD) 13.1 (3.8) 12.9 (3.3) 
Median (IQR) 12.4 (10.4-14.9) 12.6 (10.1-14.5) 
Plymouth 
Mean (SD) 16.1 (3.2) 13.6 (6.1) 
Median (IQR) 15.5 (14.0-18.6) 11.8 (10.1-14.5) 
Royal Free, London 
Mean (SD) 12.8 (3.3) 10.6 (3.0) 
Median (IQR) 12.3 (10.8-14.3) 10.1 (8.3-13.3) 
Royal London, London 
Mean (SD) 16.1 (4.3) 10.7 (3.3) 
Median (IQR) 15.5 (13.9-18.4) 10.2 (8.7-12.6) 
Sheffield 
Mean (SD) 15.1 (3.8) 10.6 (4.6) 
Median (IQR) 14.8 (13.0-16.6) 9.5 (6.9-12.1) 
Tooting 
Mean (SD) 15.3 (2.8) 10.7 (4.2) 




3.7 Virtual crossmatch 
 
A third (n=636) of the total transplants went ahead with a vXM (Table: 3.12). Of the 
19 H&I laboratories, only 8 approved vXM in greater than half of their transplants. 
There was almost an hour’s difference in median CIT between the 8 H&I 
laboratories that approved for a transplant to go ahead with a vXM in >50% of their 
























Figure 3.30 Median cold ischaemia time for H&I laboratories that perform 
vXM in more than 50% or less than 50% of kidney transplants 
 
 








3.7.1 Timing of decision to proceed to transplant with a vXM in relation 
to in situ cold perfusion  
	
In majority of the cases, the decision to proceed with a vXM was made very early in 
the process of retrieval surgery as demonstrated by the fact that the timing of the 
decision was within a minute of start of CIT (in situ cold perfusion) (Figure 3.31). 
 
 
Figure 3.31 Distribution of time interval between in situ cold perfusion and 





3.8 Pre-transplant crossmatch 
 
3.8.1 Donor tissue used for pre-transplant crossmatching 
	
Pre-retrieval peripheral blood from donor for tissue typing is used to XM with 
recipient serum to establish HLA compatibility, and this is available for testing 
before the donor organs arrive at the recipient hospital. Other donor tissues that may 
be used are spleen and lymph nodes, which are transported with the donor organs. 
The donor tissue that was used the most for pXM was spleen (50.8%). (Table 3.17). 
Of the total pXM, 79% used donor tissue other than pre-retrieval peripheral blood. 
 
	
Table 3.17 Donor tissues for pXM 
Donor Tissues for used for pXM n (%) 
Pre-retrieval peripheral blood 224 (20.5) 
Lymph node 94 (8.6) 
Spleen 554 (50.8) 











There was a significant difference in CIT between transplants that used donor pre-
retrieval peripheral blood for pre-transplant crossmatching (pXM) and those that 
used other donor tissues. (Figure 3.32) 
 
 
Figure 3.32 Impact of type of donor tissue used for pXM on cold ischaemia time 
 
 








There was a significant difference in median CIT between transplants that used pre-
retrieval peripheral blood and other donor tissue for pXM, with more than 3 hours’ 
difference in CIT. (Table 3.18, Figure 3.33) 
 
 
Table 3.18 Cold ischaemia time for kidney transplants with pre-retrieval 
peripheral blood and other donor tissues for pXM 
Donor Tissue for pXM CIT (Hours) 
Mean (SD) Median (IQR) 
Pre-retrieval peripheral blood 12.2 (3.8) 11.7 (9.7-14.2) 




















Figure 3.33 Impact of pre-retrieval peripheral blood and other donor tissue 
used for pXM on cold ishcaemia time 
 
 









The majority of pXM used donor spleen in both DBD and DCD transplant (52% and 
48, respectively). Twenty nine percent of pXM in DCD kidney transplant and 16% in 













For DCD kidney transplants:  
 
The median CIT for DCD kidney transplants that used pre-retrieval peripheral blood 
for pXM was 1.7 hours shorter than those that used other tissues (Figure 3.35). 
 
 
Figure 3.35 Impact of donor  pre-retrieval peripheral blood versus other donor 
tissue used for pXM on cold ischaemia time in DCD kidney transplants 
 
 






For DBD kidney transplants:  
 
There was more than 4 hours’ difference in median CIT between those that used pre-
retrieval peripheral blood and those that awaited lymph node and spleen for pXM 
within DBD transplants (10.8 hours and 15.1 hours, respectively), which is highly 
significant. (Figure 3.36) 
 
Figure 3.36 Impact of donor pre-retrieval peripheral blood versus other donor 
tissue used for pXM on cold ischaemia time in DBD kidney transplants 
 
 





3.8.2 Recipient serum sample used for prospective crossmatching  
	
Recipient serum samples used for pXM were either historic (stored sample) or 
current at the day of transplant (‘at transplant’ sample). ‘At transplant’ sample 
(current) was used for majority of the pXM (65%). 
 
There was a wide H&I laboratory variation in the use of current and stored recipient 
sample for pXM. Four H&I laboratories used ‘at transplant’ recipient sample only. 
Three H&I laboratories used ‘at transplant’ recipient sample in less than 10% of their 





















Figure 3.37 H&I laboratory variation in the use of stored (historic) and ‘at 










Transplants that used stored recipient serum sample for pXM had 1hour shorter 




Table 3.19 Cold ischaemia time for current at transplant or stored recipient 
serum sample used for pXM 
Recipient serum sample n Mean (SD) Median (IQR) 
Current  (‘at transplant’) 710 15.1 (4.2) 14.7 (12.4-17.2) 






















Figure 3.38 Impact of historic (stored) and current (‘at transplant’) recipient 












The difference in median CIT between type of recipient sample used (current at 
transplant or stored) for pXM was significant for DBD transplants but not for DCDs. 
(Figure 3.39) 
 
Figure 3.39 Impact of historic and current recipient sample for pXM on cold 
ischaemia time in DBD and DCD kidney transplants 
 
 
Significance: DBD: F=11.429, p=0.001 





3.8.3 Timing of reporting of pre-transplant crossmatch result in 
relation to latest of H&I staff arrival, donor sample arrival and 
recipient sample collected  
	
The median time for pXM result to be available after all facilities required to perform 
pXM are available, namely, arrival of H&I staff and delivery of donor sample to 
H&I laboratory and, obtaining recipient serum sample either historic or current 
(pXM time) was 4.3 hours (IQR 3.3-5.3). (Figure 3.40) 
 





3.8.4 Timing of reporting of pre-transplant cross match result in 
relation to in situ cold perfusion  
 
The median time interval between in situ cold perfusion (start of CIT) at retrieval 
surgery and pXM result report was 9.2 hours (IQR 6.7-11.4). (Figure 3.41) 
 
 
Figure 3.41 Distribution of time interval between in situ cold perfusion and 






3.9 Recipient preparation and impact on cold ischaemia time 
 
3.9.1 Recipient mode of travel to hospital for transplant 
 
The data for recipient mode of transport to hospital for transplant were available for 
619 transplants. The recipients used their own transport to travel to hospital in 79% 
of transplants. (Table 3.20) 
 
 
Table 3.20 Recipient mode of travel to hospital for transplant 
Recipient mode of travel n (%) 
Ambulance 33 (5.3) 
Air 4 (0.6) 
Patient’s own 491 (79.3) 
Taxi 90 (14.5) 













Recipient mode of transport to hospital for transplant did not impact CIT 
significantly. (Figure 3.42) 
 
 
Figure 3.42 Impact of recipient mode of travel on cold ischaemia time 
 
 









3.9.2 Requirement for haemodialysis immediately pre-transplant  
	
The data for whether or not haemodialysis (HD) was required for recipient 
immediately before proceeding to transplantation surgery were available for 664 
transplants of which, almost a third required HD before transplant. The average 
duration for HD was 5 hours. The median CIT was almost an hour (54 minutes) 
longer when recipient required HD before transplantation. (Table 3.21) 
 
Table 3.21 Cold ischaemia time for transplants with or without recipient HD 

















CIT in hours 
Mean (SD) Median (IQR) 
No 13.0 (3.9) 13.2 (10.1-15.7) 
Yes 14.1 (4.2) 13.9 (11.6-16.5) 
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Whether or not recipient required HD immediately before transplantation had a 
significant impact on CIT. (Figure 3.43) 
 
 
Figure 3.43 Impact of recipient requirement for HD immediately pre-transplant 
on cold ischaemia time 
 
 







Median CIT was 2.1 hours longer for transplants with a vXM where recipient 
required HD before transplant. However, there was no difference in median CIT for 
transplants with pXM whether or not recipient required HD immediately before 
transplant. (Table 3.22)  
 
Table 3.22 Impact of recipient requirement for HD immediately pre-transplant 
















CIT in hours 
pXM vXM 
No Mean (SD) 14.5 (3.1) Mean (SD) 11.1 (4.1) 
Median (IQR) 14.5 (12.6-16.3) Median (IQR) 10.2 (8.2-13.2) 
Yes Mean (SD) 15.0 (3.5) Mean (SD) 13.1 (4.7) 
Median (IQR) 14.4 (12.7-16.8) Median (IQR) 12.3 (9.4-15.9) 
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Whether or not recipient required HD before transplant impacted CIT significantly in 
vXM group, but did not impact on pXM group. (Figure 3.44) 
 
Figure 3.44 Impact of recipient requirement for HD immediately pre-transplant 
in pXM and vXM group on cold ischaemia time 
 
Significancce: vXM group: F=11.758, p=0.001 
  pXM group: F=1.699, p=0.193 
 
In the pXM group, there was no significant impact of recipient requirement for 
dialysis immediately pre-transplant in XM with donor pre-retrieval peripheral blood 
and XM with other donor tissues group on CIT. 
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3.9.3 Timing of contact of recipient for kidney transplantation after 
kidney offer accepted  
 
The data were available for 555 transplants. Three recipients were contacted before 
offer was officially accepted. One of the recipients was contacted 6 hours before, for 
DCD donor transplantation at the same hospital. The other two recipients were 
contacted 24 minutes and 25 minutes before, respectively. The median time interval 
between accepting kidney offer and contacting recipient for transplantation was 3.3 
hours (IQR1.1-1.72). (Figure 3.45) 
 
Figure 3.45 Distribution of time interval between offer accepted and recipient 




3.9.4 Timing of arrival of recipient in hospital for transplantation after 
recipient contacted  
 
The data were available for 547 transplants. The majority of the patients arrived 
within 2 hours of being contacted for transplantation (median 2.0 hours, IQR 1.4-
3.0). One of the recipients was already in hospital receiving dialysis at the time of 
contact. (Figure 3.46) 
 
Figure 3.46 Distribution of time interval between recipient contacted and 





3.9.5 Timing of arrival of recipient in anaesthetic room after porter sent 
to bring recipient to theatre  
	
Data were available for 514 patients. The median time for arrival of recipient in 
anaesthetic room after being sent for was 25 minutes (median 0.42 hours, IQR 0.28-
0.60). (Figure 3.47) 
 
Figure 3.47 Distribution of time interval between recipient sent for and arrived 






3.10 Theatre factors and impact on cold ischaemia time 
 
3.10.1 Access to theatre 
 
Majority of transplants were performed in emergency theatre (76%). Only 22% 
kidney transplants had access to dedicated transplant theatre.  
 
Median CIT for kidneys transplanted in dedicated transplant theatre was 1.4 hours 
shorter than for those transplanted in either emergency or other theatres, where 
elective procedures are carried out. Typically, access to a dedicated transplant theatre 















Table 3.23 Cold ischaemia time in relation to access to theatre 
Theatre n (%) 
CIT in hours 





148 (22.2) 12.6 4.0 4.1 24.4 12.3 (9.3-15.5) 
Emergency 
Theatre 
508 (76.3) 13.6 4.0 3.7 29.4 13.7 (11.1-16.0) 
Other 10 (1.5) 12.3 3.1 8.2 18.5 11.8 (9.8-14.5) 
	
	







3.10.2 Timing of start of transplant surgery (knife to skin) in relation to 
arrival of recipient in anaesthetic room  
	
The data were available for 525 transplants. It took an hour on average to prepare 
and ansesthetise recipient in the anaesthetic room before surgery (median 1.0 hours, 
IQR 0.75-1.2). (Figure 3.49) 
 








3.10.3 Timing of start of transplant surgery (knife to skin) in relation to 
completion of crossmatching, recipient preparation and kidney 
delivery 
	
The data were available for 103 transplants. When recipient preparation was 
complete including HD where required, pXM was complete and result reported and 
kidneys were delivered at the transplanting hospital, there was still a delay of a 
median of 3 hours (IQR 2.1-4.2) for transplant surgery start. (Figure 3.50) 
 
Figure 3.50 Distribution of time interval between completion of all preparation 





3.10.4 Time interval between informing theatre and sending for recipient 
for transplant  
 
Data were available for 304 transplants. Median time between informing theatre and 
sending for the recipient to start surgery was 1.1 hours (IQR 0.34-3.42). Some of the 
intervals were longer because theatres were informed soon after offers were accepted 
rather than waiting until all preparations were completed. (Figure 3.51) 
 
Figure 3.51 Distribution of time interval between informing theatre and sending 





3.10.5 Back table preparation time for donor kidney 
 
The data were available for 446 transplants. An average of 54 minutes was required 
for preparation of donor kidney before transplanting into recipient. (Figure 3.52) 
 









3.10.6 Timing of knife to skin after back table preparation of donor 
kidney  
 
The data were available for 440 transplants. Median time between completion of 
back table preparation and start of transplant surgery was 1.3 hours (IQR 0.6-3.9). 
The majority of transplants where transplant surgery started before completion of 
back table preparation was SPK transplants (19 out of 30). (Figure 3.53) 
 
Figure 3.53 Distribution of time interval between completion of back table 




3.10.7 Timing of removal of donor kidney from ice for anastomosis in 
recipient in relation to start of transplant surgery  
	
The data were available for 619 transplants. Median time between knife to skin at 
transplant surgery and donor kidney removed from ice for anastomosis into recipient 
was less than an hour (median 0.9 hours, IQR 0.7-1.2). (Figure 3.54) 
 
Figure 3.54 Distribution of time interval between knife to skin and donor kidney 






3.10.8 Timing of reperfusion of kidney after removal of donor kidney 
from ice at transplantation surgery 
	
The data were available for1698 transplants. Median time between removal of donor 
kidney from ice for transplantation into recipient at transplant surgery and re-
establishment of circulation and perfusion of the kidney in the recipient was 36 
minutes (IQR 0.1-0.8). (Figure 3.55) 
 
Figure 3.55 Distribution of time interval between removal of donor kidney from 





3.11 Univariate and multivariate analysis of significant factors 
contributing to cold ischaemic time 
 
Cold ischaemia time was significantly shorter (p<0.0001) when deceased donor 
kidney transplants were performed with a virtual crossmatch (vXM) as compared to 
those that were performed after prospective pre-transplant crossmatch (pXM).  
Therefore, two separate models were investigated for vXM and pXM to determine 
the factors that significantly contributed to the overall cold ischaemia time (CIT).   
 
Figure 3.56 shows the distribution of CIT for both pXM and vXM.  The median CIT 
for pXM (n=1006) is 14.3 hours (IQR 12.0 – 17.0).  The median CIT for vXM 



















































3.11.1 Prospective pre-transplant crossmatch 
 
Univariate analysis of categorical and continuous factors contributing to cold 
ischaemia time in transplants with pXM was performed. (Tables 3.24, 3.25) 
 
Table 3.24 Univariate analysis for categorical factors contributing to cold 
ischaemia time in minutes 
  
Factor Level N % p-value 
     
Donor type DBD 703 62 0.0003 
 DCD 424 38  
     
Local No 740 66 <0.0001 
 Yes 387 34  
     
Reallocated kidney No 1104 98 0.0007 
 Yes 23 2  
     
Peripheral blood No 867 79 <0.0001 
 Yes 224 21  
 Missing 36 -  
     
Current sample No  389 35 <0.0001 
 Yes 709 65  
 Missing 29 -  
     
Patient travel 1 (Ambulance) 20 6 0.5 
 3 (Patient’s own) 286 81  
 4 (Taxi) 46 13  
 5 (Other) 1 <1  
 Missing 774 -  
     
Haemodialysis  No 261 71 0.2 
required Yes 106 29  
 Missing 760 -  





Table 3.25 Univariate analysis for continuous factors contributing to cold 
ischaemia time in minutes 
  
Factor N Median IQ Range p-value 
     
Cold perfusion to kidney in ice box 867 76 61 - 93 0.04 
     
Offer accepted to latest (staff in lab, 






372 - 780 0.006 
     
Offer accepted to recipient contacted 292 108 28 – 395 0.01 
     
Recipient contacted to recipient arrived 307 120 80 – 180 0.18 
     
Kidney collected to kidney delivered 426 110 65 – 190 <0.0001 
     
Kidney on ice to kidney collected 405 56 40 – 75 0.0004 
     
Matching run complete to pXM result 1100 865 631 – 1141 <0.0001 
     
Latest (xm result known, organ 
delivered, patient ready) to transplant 
surgery started 
345 64 48 – 95 0.4 
     
Transplant surgery started to kidney out 
of ice 
354 54 39 - 75 0.77 
     
 
 
The continuous factors that were significant on their own were categorised to include 
a missing category. Multivariate analysis included following factors in the pXM 







Table 3.26 Multivariate analysis for factors contributing to cold ischaemia time 
  
Factor Level Estimate Standard 
Error 
p-value 
     
Intercept  864.13 18.8 <0.0001 
     
Peripheral blood No Baseline 
 Yes -193.7 18.9 <0.0001 
     
Kidney collected to  Less than 2hrs Baseline 
kidney delivered 2 – 4hrs 93.97 27.61 0.0007 
 More than 4hrs 138.83 36.58 0.0002 
 Missing 89.10 19.70 <0.0001 
     
Kidney reallocated No Baseline 
 Yes 153.43 51.68 0.0031 
     
Cold perfusion to Less than 1hr30 Baseline 
Kidney on ice More than 
1hr30 
63.01 18.60 0.0007 
 Missing 47.72 18.72 0.01 
     





1. Median CIT for transplants that required pXM was 14.3 hours. 
2. CIT was 3.2 hours shorter when donor pre-retrieval peripheral blood was used 
for pXM.  
3. CIT was significantly longer when kidney transport time was above 2 hours. 
4. CIT was 2.9 hours longer when kidney was reallocated. 
5. CIT was significantly longer when time between in situ cold perfusion and 




3.11.2 Virtual crossmatch 
 
Univariate analysis of categorical and continuous factors contributing to cold 
ischaemia time in transplants with vXM was performed. 
 
Table 3.27 Univariate analysis for categorical factors contributing to cold 
ischaemia time in minutes 
  
Factor Level N % p-value 
     
Donor type DBD 333 52 0.01 
 DCD 303 48  
     
Local No 390 61 0.04 
 Yes 246 39  
     
Reallocated kidney No 616 97 <0.0001 
 Yes 20 3  
     
Patient travel 1 (Ambulance) 13 5 0.9 
 2 (Air) 4 2  
 3 (Patient’s own) 205 77  
 4 (Taxi) 44 17  
 Missing 370 -  
     
Haemodialysis  No 186 67 0.003 
required Yes 91 33  
 Missing 359   










Table 3.28 Univariate analysis for continuous factors contributing to cold 
ischaemia time in minutes 
  
Factor N Median IQ Range p-value 
     
Cold perfusion to kidney in ice box 475 77 61 – 97 0.009 
     
Offer accepted to agreement to proceed 
with a vXM 
197 180 68 – 380 0.59 
     
Offer accepted to recipient contacted 222 158 39 – 375 <0.0001 
     
Recipient contacted to recipient arrived 240 120 90 – 180 0.54 
     
Kidney collected to kidney delivered 221 130 80 – 205 0.0002 
     
Kidney on ice to kidney collected 201 60 40 – 85 0.0005 
     
Matching run complete to vXM result 494 266 96 – 550 <0.0001 
     
Latest (xm result known, organ 
delivered, patient ready) to transplant 
surgery started 
255 58 45 – 75 0.1 
     
Transplant surgery started to kidney out 
of ice 
264 52 42 - 73 0.03 












Multivariate analysis included following factors in the vXM group that remained 
significant.  
 
Table 3.29 Multivariate analysis of factors contributing to cold ischaemia time 
  
Factor Level Estimate Standard 
Error 
p-value 
     
Intercept  580.00 31.82 <0.0001 
     
Donor type DCD Baseline 
 DBD 47.48 21.98 0.03 
     
Recipient on HD No Baseline 
 Yes 102.22 33.31 0.002 
 Missing 76.09 24.07 0.002 
     
Kidney reallocated No Baseline 
 Yes 338.45 60.12 <0.0001 
     
Kidney collected to Less than 2hrs Baseline 
Kidney delivered 2 – 4hrs 97.47 38.72 0.01 
 More than 4hrs 159.48 53.99 0.003 
 Missing 99.26 29.00 0.0007 





1. Median CIT for transplants with a vXM was 11.4 hours. 
2. CIT was 47 minutes longer for DBD donors than for DCD donors 
3. CIT was 2.1 hours longer when recipient required HD immediately before 
transplant. 
4. CIT was 5.3 hours longer when kidney was reallocated. 





A period of cold ischaemia is inevitable in the context of national allocation policy 
for deceased donor kidney transplantation in the UK to ensure equity of access and 
best immunological match for patients on the waiting list for transplantation. 
Because of the discrepancy in wait-listed patients requiring kidney transplantation 
with the available kidneys, there is little choice but to adopt alternative strategies 
such as accepting kidneys from extended criteria donors (ECD) to meet the demand.  
 
For a successful outcome, the length of time of cold storage is of crucial importance 
as it is recognised to be a significant risk factor for poorer outcomes including DGF, 
AR and short and long-term graft survival. Cold ischaemia time is also one of the 
few potentially modifiable risk factors in deceased donor kidney transplantation. In 
the current climate of continuing rise of use of ECD kidneys, CIT remains relevant 
and hence, there is an overarching need to minimise it. This is clearly demonstrated 
by the activities of Eurotransplant Senior Programme (Bahde et al., 2014). 
 
The study illustrates the multifactorial and complex nature of the logistical factors 
that impact CIT in relation to the national allocation scheme for DBD and regional 
allocation policy for DCD kidney transplants in the UK. The logistics of organ 
retrieval, matching, transport and transplantation are not uniform between transplant 
centres, countries and networks for organ sharing but the challenges are similar. 
Despite the obvious need for investigation, there is a dearth of studies in the current 
literature that examines the process comprehensively. A regional case-controlled 
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French study managed to reduce CIT from 21 hours to 13 hours in nationally and 
locally allocated kidneys simply by introducing a timesheet on CIT (Vacher-Coponat 
et al., 2007). This also resulted in a significant reduction in the incidence of DGF. 
Another study from Chile identified several factors relating to organ sharing, HLA 
typing and crossmatching that impacted on CIT (Elgueta et al., 2010). 
 
The single most important factor that contributed to CIT in this study was the 
introduction of a vXM policy. The Cambridge team pioneered the introduction of the 
vXM policy in the UK almost two decades ago. They have shown that selective 
omission of pre-transplant crossmatch is the most effective way to reduce CIT and 
that vXM policy can be safely introduced in carefully selected patients (Taylor et al., 
2000, Taylor et al., 2010). Decision to proceed with a vXM is a paper exercise and it 
can be achieved soon after kidney is offered for transplant, often before retrieval 
surgery. In 61% of the transplants, the decision was made before kidney was put on 
ice and 39% within a median of 2.8 hours after. Remarkably, there was only a 
minute’s delay on average for the decision to proceed with a vXM from the time of 
in situ cold perfusion at donor surgery suggesting that, effectively, vXM had zero 
impact on CIT. Despite early decision, kidney transplant surgery commenced 10 
hours (median) after vXM decision suggesting delays with transport of kidneys, 
recipient preparation and theatre availability. Although the role of vXM policy is 
compelling, a single centre Swiss study did not show a significant influence of vXM 
on CIT. It demonstrated that vXM policy influenced expeditious allocation of 
kidneys to compatible recipients, enhanced risk stratification for modified 
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immunosuppressive therapy and reduced demand on H&I staff but did not influence 
CIT significantly (Amico et al., 2011).  
 
The evidence could be used to inform national and international transplant 
communities as the purpose for adopting a vXM policy is not uniform. In the United 
States it is used solely as a tool to evaluate if a kidney is suitable to be shipped to a 
distant transplant centre for transplantation into sensitised patients. A negative pXM 
result is still a pre-requisite for a transplant to proceed. In this context, there is clear 
scope to reduce CIT by reviewing and safely implementing a vXM policy to 
establish histocompatibility between donor and recipient (Taylor et al., 2010). 
 
In comparison, pXM requires the presence of H&I staff, donor tissues and recipient 
serum sample to initiate crossmatching. The process takes 4 hours on average to 
complete. Waiting for donor tissues (spleen, lymph nodes) to arrive following 
retrieval surgery and for recipients to arrive at transplant centre before obtaining 
recipient sample add to the delay. This could be mitigated by the use of lymphocytes 
isolated from donor peripheral blood sample that was obtained prior to retrieval 
surgery for tissue typing and thus eliminating the need to wait for donor tissues to be 
delivered. Additionally, pXM could be commenced earlier if a historic recipient 
serum sample is used where suitable. Recipient’s historic serum sample without a 
recent sensitising event is sufficient for pXM and negates the need to await recipient 
arrival at transplant centre to provide a fresh sample (Bryan, 1991). Only 21% of the 
transplants that required pXM used donor pre-retrieval peripheral blood and only 
35% used historic recipient serum for histocompatibility testing. CIT, in this group, 
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could be reduced by a median of 3 hours simply by using pre-retrieval peripheral 
blood for crossmatching. Evidently, obtaining donor and recipient samples as early 
in the donor process as possible is key to reducing CIT significantly in both DBD 
and DCD transplants and hence, there is still a large scope to implement this practice 
more widely (Inotai et al., 2012, Elgueta et al., 2010).  
 
When recipients required haemodialysis immediately pre-transplant it only 
significantly impeded transplants in vXM group but did not affect those that required 
pXM. It may be possible that haemodialysis where required overlapped the time 
when pXM was being performed. As the decision to proceed with a vXM was made 
very early, often before retrieval surgery, any additional time including that for 
haemodialysis could delay transplants. Early recipient contact and their preparation 
for transplant, especially those who require haemodialysis, is likely to shorten CIT in 
the vXM group.   
 
There were still significant delays in both pXM and vXM groups despite 
confirmation of histocompatibility, arrival of kidney and completion of recipient 
preparation including haemodialysis where required suggesting there were other 
contributing factors.  
 
Factors attributing that were common to both groups were kidney transport time, 




There was a positive correlation between distance travelled by retrieved kidneys 
from 122 donor hospitals to 22 recipient transplant centres and their CITs. This was 
significant when the travel distance was above 100 miles. Kidney transport time, 
especially those beyond 4 hours, significantly impacted CIT in both pXM and vXM 
groups. However, although kidneys that were transported by air travelled the furthest 
distance (median 300 miles) their CITs were not significantly different to those 
transported by road (Blackmur, 2013). There is a clear advantage in transporting 
kidneys by air when travel distance is beyond 200 miles to shorten travel time. 
Positive correlation between kidney travel distance and CIT has also been shown 
previously in a large-scale survey of UNOS data (Salahudeen and May, 2008). 
Reasons for delays in transporting kidneys varied, with most delays occurring due to 
traffic congestion or decline by transplant centres and consequent change of 
destination and reallocation. Some of the other reasons were loss of communication, 
vehicle breakdown, delay in accepting offered kidney and lack of suitable transport.  
Kidney reallocation was one of the most significant factors adversely affecting CIT 
that is common to both the groups. Although the number of reallocated kidneys was 
small, it added an average of 4 hours to CIT. It was previously shown that CIT 
increased by an average of 7 hours each time a kidney offered through the national 
allocation scheme if initially accepted by a transplant centre for it to subsequently be 
transplanted in a different patient (Johnson et al., 2010b). There is a clear need to 
keep reallocation to the minimum and, if needed, to make the decision before the 
kidney leaves donor hospital to avoid unwarranted extra transport time. In majority 
of the cases it is attributed to recipients being unfit for transplantation at the time of 
offer. This highlights the need for regular assessment and notification of any illness 
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for wait-listed patients to avoid reallocation to a different patient. In SPK transplants, 
15% of pancreas had to be discarded because of unsuitability or damage to the organ 
and the kidneys were reallocated to different recipients. Thorough assessment of the 
pancreas for suitability for transplant at the time of retrieval would decrease the 
incidence of such reallocation.  
 
Data for recipient preparation and theatre activities were limited. There was a 3-hour 
delay for transplant surgery to start, despite XM result, kidney and recipient being 
ready. Evidently, factors relating to availability of theatre, anaesthetists, surgeons 
and theatre staff also had an impact on CIT. An early part of the study included 
interrogation of staff and survey of logistics and local practices at all renal transplant 
units in the UK. As shown in previous studies, lack of a dedicated theatre for 
transplant was identified as the major rate-limiting factor (Seow et al., 2006, Elgueta 
et al., 2010, Vacher-Coponat et al., 2007). The majority (76%) of transplants were 
performed in emergency theatres and CIT for transplants that were performed in a 
dedicated transplant theatre was significantly shorter. Reasons most commonly 
identified for this include vying for theatre space with emergency cases and 
availability of anaesthetists and theatre staff. Significant number of transplants 
occurs out of hours when there is limited access to theatre and fewer theatre staff and 
anaesthetists at night times and during weekends (Seow et al., 2006). A change in 
policy prioritising adequate theatre access at all hours should be pursued and 




The data collected for H&I, donor activities and kidney transport were 
comprehensive, making the relevant findings highly significant. One of the 
limitations of the study is the paucity of data surrounding activities at transplant 
centres relating to recipient, theatre and surgical factors. The structure and logistics 
of the recipient transplant centres were varied and complex, involving numerous 
members of the clinical team. Collection of information for the activities depended 
on individual members of the clinical team who provided 32-35% of data for 
recipient and theatre activities in the study. This was supplemented by information 
collected by interviewing members of the staff at all centres early in the study 
process. Although this data was limited, the study has identified significant factors 
that remain pertinent.  
 
An alternative method that could be used to analyse data in the study is comparing 
transplants between DBD and DCD donors. A multivariate model incorporating the 
categorical and continuous factors that were found to be significant in the two groups 
could then be developed for multivariate analysis. 
 
With the increasing use of newer alternative organ preservation techniques such as 
hypothermic machine perfusion and normothermic regional perfusion, static cold 
storage technique may become less universal. However, as these techniques are still 
evolving and cold storage remains the principal method for kidney preservation and 
transport between donor hospital and recipient transplant centre, CIT remains an 
important factor in deceased donor transplantation (Hameed et al., 2016, Lam et al., 
2013).   
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Figure 4.1 shows some of the important areas for intervention to make gains in the 
overlapping events in the kidney timeline.  
 
Figure 4.1 Logistical areas for possible intervention to reduce CIT 
 
 
1. All centres should adopt a vXM policy and use vXM in as many transplants 
as possible.  
 
2. One of the novel measures that could be utilised in this era of modern 
technologies is to introduce tracking system for the organs in collaboration 
with the transport providers that will provide real-time tracking of the organs 
so that preparation of recipients, staff and theatre could be carried out in a 













































3. Recipients requiring HD immediately pre-transplant should be identified 
earlier in the process and HD should be started sooner to limit delay.  
 
4. There should be a dedicated theatre for transplants in each centre so that there 
is sufficient and timely access to theatre for transplants to take place as this 
has been identified as one of the significant rate-limiting factors when kidney, 





















The logistics of deceased donor kidney transplantation are complex and 
multifactorial, encompassing coordinated efforts between various specialities and 
personnel across the UK for the best possible outcome. CIT is recognised as one of 
the principle and potentially modifiable factors that can lead to better transplant 
outcomes. The study sought to comprehensively investigate the process to identify 
areas for delay along the course of kidney journey with a view for expediting the 
process, where possible, to shorten the journey and consequently, CIT.  
 
Introduction of a vXM policy where suitable was the crucial factor identified to 
shorten CIT, and efforts should be made to adopt and increase the practice.  Earlier 
recipient contact for those who require haemodialysis immediately before transplant 
and are suitable to proceed with a vXM, and use of donor pre-retrieval peripheral 
blood and historic recipient serum sample for crossmatching for those requiring 
pXM can reduce CIT further. Access to dedicated transplant theatre round the clock, 
minimising reallocation of kidneys and using faster mode of transport for kidneys if 
distance is greater than 100 miles can also expedite the process 
  
The possible introduction to opt out legislation for deceased organ donation in 
Scotland and England will also have an impact on organ donor numbers. Therefore, 
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Logistical Factors Influencing Cold Ischemia
Times in Deceased Donor Kidney Transplants
Sussie Shrestha, MBBS,1 Lisa Bradbury, MSc,2 Matthew Boal, MBBS,3 James P. Blackmur, MBChB, MRCS,1
Christopher J. E. Watson, PhD, FRCS,4 Craig J. Taylor, PhD,5 John L. R. Forsythe, MD, FRCS,1
Rachel Johnson, MSc,1 and Lorna P. Marson, MD, FRCS1
Background.Prolonged cold ischemia time (CIT) is associated with a significant risk of short- and long-term graft failure in de-
ceased donor kidney transplants across the world. The aim of this prospective longitudinal study was to determine the importance
of logistical factors on CIT.Method.Data on 1763 transplants were collected prospectively over 14months from personnel in 16
transplant centers, 19 histocompatibility and immunogenetics laboratories, transport providers, and National Health Service Blood
and Transplant.Results. The overall mean CITwas 13.8 hours, with significant center variation (P < 0.0001). Factors that signif-
icantly reduced CITwere donation after circulatory death (P = 0.03), shorter transport time (P = 0.0002), use of virtual crossmatch
(XM) (P < 0.0001), and use of donor blood for pretransplant XM (P < 0.0001). The CIT for transplants that went ahead with a virtual
XMwas 3 hours shorter than those requiring a pretransplant XM (P < 0.0001). There was amean delay of 3 hours in starting trans-
plants despite organ, recipient, and pretransplant XM result being ready, suggesting that theater access contributes significantly to
increased CIT.Discussion. This study identifies logistical factors relating to donor, transport, crossmatching, recipient, and the-
ater that impact significantly on CIT in deceased donor renal transplantation, some of which are modifiable; attention should be
focussed on addressing all of these.
(Transplantation 2016;100: 422–428)
Delayed graft function (DGF), which can be defined as therequirement for dialysis in the first 7 days after trans-
plantation, occurs in a significant number of deceased donor
(DD) renal transplants, cited as between 25% and 50%,1
and is associatedwith a significantly increased risk of graft loss
over the years after transplantation, higher serum creatinine at
1 year, and an increased risk of acute rejection.2 Risk factors
for DGF include cold ischemia time (CIT), donor factors, such
as age and serum creatinine, recipient factors, such as body
mass index, and immunological and logistical factors.3 Of
these, prolonged CIT has been shown to be the most signifi-
cant individual factor in predicting DGF: Irish et al4 reported
that for every hour of increased CIT, there was a 4% increased
risk of DGF. Cold ischemia time is defined as the time from
commencement of cold perfusion at the time of donor surgery
to the removal of the kidney from ice in the recipient center
and is affected by a complex logistical pathway that includes
kidney allocation, transport, crossmatching, preparation of
the recipient, and access to theater.
Kidneys that are particularly susceptible to ischemic dam-
age and DGF are those from DDs after circulatory death
(DCD), and extended criteria donors (older (>60 years)
donors and those with comorbidities, for example, cardiovas-
cular disease).5 With increasing numbers of patients waiting
for transplantation, more such organs are accepted and thus
CITwill remain an important consideration in DD transplan-
tation.6,7 We prospectively studied the impact of individual
logistical factors on CIT, relating to events from the time of
kidney retrieval at the donor hospital to kidney being removed
from ice in the recipient center (Figure 1). Although logistical
details vary between nations and organ sharing schemes, our
findings are worthy of careful reflection internationally.
MATERIALS AND METHODS
Data Collection
Prospective data collection was performed between June
2011 and the end of July 2012. Before commencement of
the data collection, all United Kingdom transplant centers,
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specialist nurses for organ donation and histocompatibility
and immunogenetics (H&I) laboratories were visited tomax-
imize participation with the study. The studywas funded from
a research grant from National Health Service Blood and
Transplant (NHSBT), and was approved by the Kidney Advi-
sory Group, which advises NHSBT on all aspects of kidney
transplantation within the United Kingdom. Staff involved in
the data collection included specialist nurses for organ dona-
tions, H&I staff, transport providers, recipient transplant
coordinators, transplant surgeons/fellows/specialist registrars,
nephrologists, theater and ward staff, and NHSBT.
Data were obtained on DD kidney only and simultaneous
pancreas andkidney (SPK) transplants from16of the 22 invited
transplant centers (6 centers declined to participate) along with
all 19 H&I laboratories (supporting all 22 transplant centers),
with the aim of determining whether there are specific areas
on which to focus efforts to reduce CITs. The CIT was calcu-
lated from United Kingdom Transplant Registry data held by
NHSBTandwas defined as the time from in situ cold perfusion
in donor at the time of retrieval to the time of removal of kidney
from ice for transplantation in recipient. This was available for
all transplants performed in all 22 centers.
Factors that were considered to be relevant for this study
were agreedwith a nationalmultidisciplinary team, including
transplant surgeons, H&I scientists, and statisticians. In ad-
dition, draft documents were circulated to the heads of trans-
plant centers for their input. Categorical and continuous data
were collected along the kidney timeline from the time of
organ donation at the donor hospital to completion of trans-
plantation at recipient hospital on four different data collec-
tion forms. We focused on 5 key logistical areas, namely,
donor operation, organ transport, laboratory tests, including
the match run and the crossmatch (XM), recipient prepara-
tion and theater, as shown in Figure 1. For clarity, the duty
office at NHSBT performs the match run once the donor
HLA type is known; this is matched to the recipient pool.
We examined different factors within each of these key areas
to identify those that impacted on CIT.
A national database was set up, and data input was done
prospectively. Data were checked for errors, and each outlier
was examined by rechecking them against the original forms
as well as with the rest of the data for the corresponding
transplant. We excluded transplants that did not proceed
despite retrieval of organs, and kidneys that were trans-
planted with organs other than pancreas. When 2 kidneys
were transplanted in a single recipient (double kidney trans-
plant), the onewith the longer CITwas excluded. Data on re-
cipient and theater times that were inconsistent with the
rest of the data and those that had a discrepancy of more
than 1 hour from NHSBT data were excluded (n = 52
transplants). Transplants with no virtual crossmatch
(vXM) or pretransplant XM (pXM) information were ex-
cluded. Data cleansing was undertaken before the final
analysis: 5% of the data were selected randomly at regular
intervals, and each one was checked against the original
forms and records to establish excellent quality assurance
of the input data. An error rate less than 1% was consid-
ered acceptable. Data were collected for almost 100% of
donor and H&I data for that period, with 37% of trans-
port data, 32% of recipient, and 35% of theater data from
the 16 participating centers.
Crossmatch Terminology
Several centers in the United Kingdom have adopted selec-
tive omission of the pXM in potential recipients who are at
low immunological risk,8 and this has been shown to be safe
and effective at reducing CIT.9
For clarification in this study, we will use the term pXM
for those transplants that required full XM testing to be per-
formed before start of surgery, and vXM for those in whom
the prospective pretransplant donor XM was omitted and it
was safe to proceed without waiting for the XM test to be
performed. The formal XM test was performed retrospec-
tively, and there have been no cases of unexpected XM posi-
tivity after transplantation.
Statistical Analysis
General demographics of DDkidney and SPK transplanta-
tion in the 14-month period included number and type of
donors, kidneys, transplants, recipients, allocation, and real-
location across the United Kingdom transplant centers. All
relevant time intervals were collected in hours. Various time
intervals between donor notification and completion of
transplant surgery were examined, namely, times of retrieval
surgery, transport of organs, donor HLA typing and cross-
matching, recipient preparation and transplant theater.
Donor-related categorical data included in the analyses were
type of donor (donation after brain death [DBD] or DCD)
and donor tissues used for crossmatching. Transport-related
categorical data was mode of organ transport, H&I-related
data were type of crossmatching, types of donor tissues and
recipient blood samples used if pXM test done, recipient-
related categorical factors included mode of recipient travel
to the transplant center, requirement for haemodialysis imme-
diately before transplant and requirement for current recipi-
ent serum sample for crossmatching. The sole theater-related
categorical factor included was whether the transplant was
performed in an emergency or transplant-dedicated theater.
All data within the study period were included in the uni-
variate analysis. Parametric tests were performed to assess
differences in CIT across transplant centers and XM type,
variation in XM across transplant centers and variation in
practice around the use of donor samples for pXM. A general
linear model was used to determine the contributions of var-
ious factors and time intervals to the CIT. Because of the
FIGURE 1. Logistics of deceased donor transplantation in the
United Kingdom. DO indicates duty office; HD, hemodialysis.
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missing data, time intervals were analyzed categorically.
The distribution of each of the time intervals was used to de-
cide appropriate categories. Factors that were found to be
significant in the univariate analyses were incorporated in
the multivariate modelling. Only significant factors in the
multivariate modelling were included in the final model.
P values less than 0.05 were considered significant. All
analyses were performed using SPSS version 19, IBM, UK,
and SAS version 9.4.
Intercept Description
The intercept is the median CIT if all other factors are set
to zero (the baseline).
RESULTS
General Demographics
Data include information for 1763 single/double/en-bloc
kidney only and SPK transplants from across the United
Kingdom. Of those, 1586 (90%) were kidney only and
177 (10%) SPK transplants. Fifty-five of the 1586 kidney
only transplants were double and 4 were en-bloc kidney
transplants. The DCD kidneys constituted more than a third
(41%) of the transplants, and the majority of kidneys (64%)
were shipped between centers. Forty-three (2%) kidneys
were reallocated: 32 were reallocated locally, and 11 were
reallocated to a different transplant center.
Cold Ischemia Times
The overall mean CIT for kidney transplants in all trans-
plant centers was 13.8 hours [SD, 4.5; Interquartile range
(IQR) 10.7-16.4]. The shortest recorded CIT was 3.7 hours,
and the longest was 33.1 hours.
There was significant center variation inmeanCIT ranging
between the shortest of 12.0 hours and the longest of 20.4
hours in the 22 centers (F = 10.060, P < 0.0001), as shown
in Figure 2.
The most significant factor affecting CIT overall was the
adoption of a vXM policy. Transplants that required a
pXM had a CIT that was 3 hours longer than those where
the XM test was omitted and proceeded directly to transplant
based on a negative vXM (Figure 3, P < 0.0001). There was
significant center variation in the number of transplants per-
formed using vXM; indeed at the time of the study two
centers had not adopted a vXM policy (P < 0.0001). Be-
cause of the key role played by the type of XM performed
and the fact that the kidney pathway diverges depending on
whether the transplant requires a pretransplant crossmatch
or not, the analysis was performed separately for vXM and
pXM groups.
If a pXM is required, this can be performed using donor
peripheral blood obtained preretrieval, or lymph node and
spleen that are taken at the time of retrieval and accompany
the organs to the recipient center. We sought to determine
whether there was variation in practice with regard to the
use of donor tissue for pXM because this was likely to signif-
icantly alter the timing of availability of the XM result. There
were significant differences in laboratory practice, with 1 lab-
oratory performing approximately 89% pXM on peripheral
FIGURE 3. The impact of the crossmatch type on CIT; transplants that proceeded based on a virtual cross match (omitting the pre-transplant
crossmatch test) had a median CITof approximately 3 hours less than those that required a prospective cross match. (t test, P < 0.0001). A,
Pretransplant cross match. B, Virtual cross match.
FIGURE 2. There was significant variation in CIT between centers
across the United Kingdom, expressed as box and whisker plot with
mean. The shortest mean CIT was 12.00 hours and the longest of
20.36 hours, compared in all 22 centers (F = 10.060, P < 0.0001).
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blood, whereas other laboratories were dependent on the
arrival of lymph nodes and spleen in all cases (Figure 4).
The factors that were included in a univariate analysis
for both vXM and pXM groups are outlined in Table 1 (cat-
egorical) and Table 2 (continuous). These include factors
pertaining to each stage of the kidney journey from donor
to recipient, and key timelines of the process.
Factors Affecting CIT in Transplants Requiring pXM
Test (Univariate Analysis)
In the pXM group, several factors contributed signifi-
cantly to CIT in univariate analysis: CIT was significantly
shorter in DCD transplants than DBD (P = 0.0003); kidneys
that were transplanted locally had a shorter CIT than those
that were exported (P < 0.0001), and CIT was prolonged if
kidneys were reallocated either locally or to a second center
(P = 0.0007). Importantly, if the pXM was performed using
donor peripheral blood obtained before start of retrieval,
rather than donor lymph nodes and spleen obtained at re-
trieval and transportedwith the organs, CITwas significantly
reduced (P < 0.0001). Similarly, if stored recipient blood was
available for crossmatching purposes, this resulted in a signif-
icant reduction in CIT (P < 0.0001). Continuous variables
that were found to contribute to CIT in the pXM group were
transport times, time taken from in situ cold perfusion to the
kidney boxed ready for transport, time between the offer
made and the kidney accepted by the recipient center, and
time to obtain the XM result. Once the kidney had arrived
and pXM result is known, any further delay in proceeding
with the transplant was documented and was found to have
a significant impact on CIT.
Factors Affecting CIT in Transplants Undertaken Using
vXM (Univariate Analysis)
Significant factors in univariate analysis were donor type
(DBD/DCD) (P = 0.01), and whether the kidney was allo-
cated locally or imported from another region (P = 0.04). In
the small number of kidneys that were reallocated, this had
a significantly detrimental impact on CIT (P < 0.0001). Re-
quirement for recipient hemodialysis before transplantation
also had a significant impact (P = 0.003). Continuous factors
thatwere relevant included timing from cold perfusion to kid-
ney boxed ready for transport, offer accepted to contacting
the recipient, timing of kidney collection, and its transport.
Multivariate Analysis of Factors Affecting CIT
All factors that were significant in univariate analyses
were considered in multivariate modelling, and factors that
FIGURE 4. Laboratory variation in practice around use of donor
samples for pretransplant crossmatch.
TABLE 1.
Categorical factors included in the univariate analysis for pXM and vXM groups
Factor Level
Pretransplant crossmatch Virtual crossmatch Total
N % N % N %
Donor type DBD 703 62 333 52 1036 59
DCD 424 38 303 48 727 41
Local No 740 66 390 61 1130 64
Yes 387 34 246 39 633 36
Reallocated kidney No/unknown 1104 98 616 97 1720 98
Yes 23 2 20 3 43 2
Peripheral blood No 867 79 — 867 79
Yes 224 21 — 224 21
Missing 36 — 36 —
Current sample No 389 35 — 389 35
Yes 709 65 — 709 65
Missing 29 — — 29 —
Recipient mode of travel to hospital Ambulance 20 6 13 5 33 5
Air 0 0 4 2 4 1
Patient’s own 286 81 205 77 491 79
Taxi 46 13 44 17 90 15
Other 1 <1 0 0 1 <1
Missing 774 — 370 — 1144 —
Hemodialysis required by recipient No 261 71 186 67 447
Yes 106 29 91 33 197
Missing 760 — 359 1119
Local: when a kidney, retrieved at one of the hospitals within a defined geographical region, is transplanted at the designated transplant unit for that region.
Reallocation: when a kidney, which was initially accepted for transplantation in a particular recipient at a transplant unit, is subsequently allocated to a second recipient at the same or a different hospital.
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remained significant are shown in Table 3. Key findings in the
pXM group are shown in Table 3A: if peripheral blood is
used for pXM, CIT is reduced by more than 3 hours. Factors
that led to an increased CIT are travel times (adding between
1.5 and 2.3 hours) or kidney reallocation (+2.6 hours). In ad-
dition, once the kidney had arrived and the pXM result was
TABLE 2.
Continuous factors included in the univariate analysis for pXM and vXM groups
Pretransplant crossmatch, h Virtual crossmatch, h
Factor N Median IQ range N Median IQ range
Cold perfusion to kidney in ice box 867 1.27 1.02-1.55 475 1.28 1.02-1.62
Offer accepted to latest of staff in lab, donor sample arrive, or recipient sample arrive 308 9.42 6.20-13.00 — —
Offer accepted to agreement to proceed with a vXM — — — 197 3.00 1.13-6.33
Offer accepted to recipient contacted 292 1.80 0.33-6.58 222 2.63 0.65-6.25
Recipient contacted to recipient arrived 307 2.00 1.33-3.00 240 2.00 1.50-3.00
Kidney on ice to kidney collected 405 0.93 0.67-1.25 201 1.00 0.67-1.42
Kidney collected at donor hospital to kidney delivered to recipient center 426 1.83 1.08-3.17 221 2.17 1.33-3.42
Matching run complete to pXM result 1100 14.42 10.52-19.02 — —
Matching run complete to agreement to proceed with a vXM — — 494 4.43 1.60-9.17
Latest (XM result known, organ delivered) to transplant surgery started 342 3.30 2.28-5.17 82 3.82 2.53-6.00
Transplant surgery started to kidney out of ice 354 0.90 0.65-1.25 264 0.87 0.70-1.22
TABLE 3.
Multivariate analysis of factors affecting cold ischemia time for (A) pXM group and (B) vXM group
Factor Level Estimated change in CIT, h Standard error P
(A) Pretransplant crossmatch
Intercept 13.3 0.4 <0.0001
Peripheral blood No Baseline
Yes −3.4 0.3 <0.0001
Kidney collected to kidney delivered Less than 2 h Baseline
2-4 h 1.5 0.5 0.0007
More than 4 h 2.3 0.6 0.0002
Missing 1.3 0.3 <0.0001
Kidney reallocated No Baseline
Yes 2.6 0.8 0.0019
Cold perfusion to kidney on ice Less than 1 h 30 min Baseline
More than 1 h 30 min 1.1 0.3 0.0004
Missing 0.7 0.3 0.02
Latest (XM result known, organ delivered) to transplant surgery started Less than 5 h Baseline
5-9 h 2.1 0.5 <0.0001
More than 9 h 5.7 1.0 <0.0001
Missing 1.5 0.3 <0.0001
(B) Virtual crossmatch
Intercept 8.7 0.7 <0.0001
Donor type DCD Baseline
DBD 0.8 0.4 0.03
Recipient on HD No Baseline
Yes 1.3 0.6 0.02
Missing 1.3 0.4 0.002
Kidney reallocated No Baseline
Yes 5.7 1.0 <0.0001
Kidney collected to kidney delivered Less than 2 h Baseline
2-4 h 1.6 0.6 0.01
More than 4 h 2.8 0.9 0.002
Missing 1.8 0.5 0.0004
Latest (proceed with vXM, organ delivered) to transplant surgery started Less than 5 h Baseline
5-9 h 2.7 1.1 0.01
More than 9 h 7.6 1.7 <0.0001
Missing 0.8 0.7 0.2
Explanation of ‘intercept’ is provided in the Methods section.
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known, a further delay in start of surgery had a significant
detrimental impact on CIT. This was also significant in the
context of the vXM group (Table 3B), leading to a significant
delay in commencement of surgery and thus increasing CIT.
Other factors that remained significant in the vXM group
were the patient requiring hemodialysis before transplanta-
tion, travel time, and kidney reallocation.
DISCUSSION
Cold ischemia time is one of the few modifiable factors
that have been identified as a significant risk factor for
DGF, with long-term implications for graft survival in DD
renal transplants.2,10-12 It is likely that, in the current era of
accepting kidneys from extended criteria donors, and DCD
donors, CIT will continue to play a significant role, and
should be minimized, as evidenced by the experience of the
Eurotransplant Senior program.13
We have examined logistical factors that contribute to CIT
in the context of national (DBD) and regional (DCD) alloca-
tion of DCD kidneys within the United Kingdom. Organ
retrieval, transport, and implantation logistics vary between
countries and organ sharing networks; however, studies
examining these are lacking, despite a clear need for such in-
vestigation.14 Thus, we consider the international relevance
of factors identified in this study based on current literature
available. One regional French study examining the impact
of the introduction of a timesheet onCIT in locally and nation-
ally allocated kidneys found that the introduction of such a
time sheet alone reduced CIT from 21 hours to 13 hours in a
case control study.15 Another review of factors affecting CIT
inChile highlighted the impact of kidney sharing, reallocation,
and factors pertaining to HLA typing and crossmatching.16
The factor that contributed most significantly to CIT
was the introduction of a vXM policy in patients that were
deemed suitable for such: these patients have low immunolog-
ical risk, with known HLA antibody profile and few unaccept-
able antigens. This finding requires further interrogation: the
prolonged CIT in patients requiring a pXMmay be due to other
factors relating to their more complex sensitisation profiles. A
study from Cambridge demonstrated that the introduction of a
virtual crossmatch policy in carefully selected patients could be
undertaken safely and leads to an effective reduction in CIT.8,9
It is likely that lessons can be learned internationally from
this finding. In the United States, virtual crossmatching is
adopted to predict whether or not a kidney should be shipped
to a distant center for transplantation into a sensitized pa-
tient, but the pXM is still performed on arrival of the kidney
at the recipient center. A review of this policy with the intro-
duction of a vXM policy is likely to lead a reduction in CIT,
and might be safely introduced.9 However, introduction of a
vXM policy does not always result in reduced CIT, as has
been shown recently in a Swiss study: the policy led to im-
proved allocation, reduced workload on the H&I staff, and
improved risk stratification for modified immunosuppres-
sion, but CITwas the same in both groups.17
Factors that were common to both pXMand vXMgroups
were travel time, kidney reallocation, and a delay in gaining
access to theater, despite the availability of the XM result
and the kidney having arrived at the recipient hospital. When
members of staff were interviewed at all transplanting centers
across the United Kingdom as an early part of this work, the
most commonly perceived reason for prolonged CIT was
lack of access to theater, due to competing interests of emer-
gency cases, and availability of anesthetic and theater staff. It
has been previously shown that more than 50% of kidney
transplants are performed overnight and at weekends when
there are fewer operating rooms and less staff coverage (nurs-
ing, anaesthetic)18 and we must implement policy changes
that prioritize sufficient theater access out of hours if we are
to continue to strive tominimize CITand optimize outcomes.
One limitation of the study is the paucity of data relating to
transport, recipient, and surgical factors. The study relied on
information being collected by individual members of the
clinical team at the recipient hospital, resulting in approxi-
mately 33% data being collected. Formal collection of trans-
port times has now been built into the contract of transport
providers. Despite this shortcoming, significant and impor-
tant factors have been identified, which remain relevant.
With the introduction of novel technologies that aim to
improve perfusion and organ preservation, such as machine
perfusion andnormothermic regional perfusion, static cold stor-
agemay become a less commonly adopted technique.However,
although organs continue to be transported on ice between cen-
ters to optimize transplant outcomes, CIT remains an important
factor. This study has demonstrated specific logistical factors
that can be addressedwith the potential tominimizeCIT further
and has international relevance because CIT is recognized as a
key factor contributing to DGF.
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without reference to a standard. 
Quantitative research -may involve evaluating or 
comparing interventions, particularly new ones.  
Qualitative research – usually involves studying 
how interventions and relationships are 
experienced.  
Involves an intervention in use 
ONLY. (The choice of 
treatment is that of the clinician 
and patient according to 
guidance, professional 
standards and/or patient 
preference.)  
Involves an intervention in use 
ONLY. (The choice of 
treatment is that of the clinician 
and patient according to 
guidance, professional 
standards and/or patient 
preference.)  
Usually involves collecting data that are additional 
to those for routine care but may include data 
collected routinely. May involve treatments, 
samples or investigations additional to routine care.  
Usually involves analysis of 
existing data but may include 
administration of simple 
interview or questionnaire.  
Usually involves analysis of 
existing data but may include 
administration of simple 
interview or questionnaire.  
Quantitative research - study design may involve 
allocating patients to intervention groups.  
Qualitative research uses a clearly defined sampling 
framework underpinned by conceptual or 
theoretical justifications.  
No allocation to intervention 
groups: the health care 
professional and patient have 
chosen intervention before 
clinical audit.  
No allocation to intervention 
groups: the health care 
professional and patient have 
chosen intervention before 
service evaluation.  
May involve randomisation  No randomisation  No randomisation  
ALTHOUGH ANY OF THESE THREE MAY RAISE ETHICAL ISSUES, UNDER CURRENT GUIDANCE:-  
RESEARCH REQUIRES R.E.C. REVIEW  AUDIT DOES NOT 
REQUIRE R.E.C. REVIEW  
SERVICE EVALUATION 




















Kidney Donation and Retrieval Information 
 
















1. Please complete this form for every deceased donor. 
2. This form can be completed either manually or electronically. 
3. The study coordinator will greatly appreciate it if you could complete this form as clearly as 
possible and with black ink only. 
4. When complete, please return the form to the coordinator centre in one of the following ways: 
  
 Post: 
  Sussie Shrestha 
  C/O Ms Lorna Marson 
  Consultant Surgeon 
  Royal Infirmary of Edinburgh 
  51 Little France Crescent  
  Edinburgh  
  EH16 4SA 
 
 Fax No: 0131 242 3617 
 
 Email: sussie.shrestha@nhs.net 
 
4.  If you have any queries, please do not hesitate to contact the study coordinator, Ms Sussie 




































   




ODT Donor No:  
Type of Donor:                        DBD                            DCD  
DONOR HOSPITAL 
Hospital name:                                             
Date retrieval started (dd/mm/yyyy):  
 Date (dd/mm/yyyy) 24hrTime(hh:mm) 
Time blood samples dispatched to H&I    
Time of circulatory arrest   
Time of in situ cold perfusion   
Time kidney on ice box RIGHT kidney   
Time kidney on ice box LEFT kidney   
Kidney collection time RIGHT kidney   
Kidney collection time LEFT kidney   







Form completed by (please print):  




Appendix 4: Questionnaire for Histocompatibility and Immunogenetics 












HLA Crossmatching Information 
 


















1. Please complete this form for each recipient of a deceased donor kidney and kidney + pancreas 
transplant. 
2. This form can be completed manually or electronically. 
3. The study coordinator will greatly appreciate it if you could complete this form as clearly as 
possible and with black ink only. 
4. When complete, please return the form to the coordinator centre in one of the following ways: 
  
 Post: 
  Sussie Shrestha 
  C/O Ms Lorna Marson 
  Consultant Surgeon 
  Royal Infirmary of Edinburgh 
  51 Little France Crescent  
  Edinburgh  
  EH16 4SA 
 
 Fax No: 0131 242 3617 
 
 Email: sussie.shrestha@nhs.net 
 
5. If you have any queries, please do not hesitate to contact the study coordinator, Ms Sussie 

















ODT Donor No:  
Local                                Import  
H&I LABORATORY 
Location of Laboratory:  
RECIPIENT DETAILS 
Patient Transplant Centre:  
 
 
For Recipient 1: 
ODT Recipient No:  
Virtual crossmatch (omitting the crossmatch test before transplant):   Yes                 No  
 Date(dd/mm/yyyy) 24hrTime(hh:mm) 
Time offer received   
Time agreed to proceed with a virtual crossmatch    
If prospective pre-transplant crossmatch undertaken; donor tissues used: 
                 Lymph node           Spleen           Pre-retrieval peripheral blood  
Requirement for current recipient crossmatch sample:      Yes                       No  
If prospective pre-transplant crossmatch performed; Date(dd/mm/yyyy) 24hrTime(hh:mm) 
Time staff arrived in laboratory to perform crossmatch   
Time donor crossmatch specimens received   
Time recipient crossmatch specimens received   
Time recipient crossmatch result reported   
 
For Recipient 2: 
ODT Recipient No:  
Virtual crossmatch (omitting the crossmatch test before transplant):   Yes                 No            
 Date(dd/mm/yyyy) 24hrTime(hh:mm) 
Time offer received   
Time agreed to proceed with a virtual crossmatch   
If prospective pre-transplant crossmatch undertaken; donor tissues used: 
                 Lymph node           Spleen           Pre-retrieval peripheral blood       
Requirement for current recipient crossmatch sample:      Yes                       No  
If prospective pre-transplant crossmatch performed; Date(dd/mm/yyyy) 24hrTime(hh:mm) 
Time staff arrived in laboratory to perform crossmatch   
Time donor crossmatch specimens received   
Time recipient crossmatch specimens received   
Time recipient crossmatch result reported   
 





Number of back-up crossmatch performed simultaneously: Virtual:        Actual:  
 
Form completed by (please print):  
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Kidney Transplant Information 
 




















1. Please complete this form for each potential deceased donor kidney and kidney + pancreas 
recipient who is admitted for transplant and for kidneys received but subsequently reallocated. 
2. This form can be completed manually or electronically. 
3. The study coordinator will greatly appreciate it if you could complete this form as clearly as 
possible and with black ink only. 
4. When complete, please return the form to the coordinator centre in one of the following ways: 
  
 Post: 
  Sussie Shrestha 
  C/O Ms Lorna Marson 
  Consultant Surgeon 
  Royal Infirmary of Edinburgh 
  51 Little France Crescent  
  Edinburgh  
  EH16 4SA 
 
 Fax No: 0131 242 3617 
 
 Email: sussie.shrestha@nhs.net 
 
5. If you have any queries, please do not hesitate to contact the study coordinator, Ms Sussie 



















ODT Donor No:  
RECIPIENT DETAILS 
ODT Recipient No:  
Hospital No:  
Kidney allocated:                     RIGHT                             LEFT  
Organ transplanted:          Kidney only       Kidney & Pancreas  
RECIPIENT HOSPITAL 
Transplant Centre:  
Recipient Preparation: Date(dd/mm/yyyy) 24hrTime(hh:mm) 
Time offer received   
Time offer accepted   
Time recipient contacted   
Time recipient arrived on ward   
Time kidney arrived at the hospital   
Recipient’s mode of travel:      Ambulance              Air             Patient’s own             Taxi:  
Recipient required haemodialysis pre-transplant Yes              No  
If yes, time:                                                  Start:   
                                                                   Finish:   
Time crossmatch result received   
Transplant cancelled                    Yes         No                                            
If yes, reason:  
Kidney reallocated:              Locally          Other centres                  No  
Reason for reallocation:  
If reallocated locally, please complete a separate form for second recipient                                     
If kidney transferred to a different centre:  
Time ODT informed   
Time organ collected   
THEATRE TIMES 
Theatre where transplant performed:   Transplant theatre       Emergency theatre       Other  
 Date(dd/mm/yyyy) 24hrTime(hh:mm) 
Time theatre staff informed transplant can proceed   
Back table preparation time:                       Start:        
                                                                    Finish:   
Time patient sent for   
Time patient arrived in anaesthetic room   
Time of start of surgery (knife to skin)   
Time kidney removed from ice for anastomosis   
Time of reperfusion   
If SPK:  
Back table preparation time for pancreas       Start:   
                                                                       Finish:   
Time start of surgery for pancreas (knife to skin)   
Time pancreas removed from ice for anastomosis   
Time of reperfusion of pancreas   
Reason for delay if any:  
 
 
Form completed by (please print):    
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Data from TFT 
 
TRANSPORT TIMES 
Mode of transport of organ: 
                           Ambulance:            Blue-light:    Yes           No  
                                         Air:  
         Taxi:  
 Date(dd/mm/yyyy) Time(hh:mm) 
Time organ collected 
 
  
Time of arrival at recipient centre   







































Hospital Name:  
Organs transplanted in the Unit: 




Access to theatre for kidney transplant:       
                                  Dedicated transplant theatre:                In hours           Out of hours  




No. of consultant transplant surgeons active in DD kidney transplant in the Unit:  
Local kidney allocation policy of transplant Unit: 
                                 Recipients contacted one at a time  
                                Group of recipients identified  




Local allocation policy for DCD or any other locally allocated kidney and DBD kidney not 





Does the transplant unit have options for doing simultaneous kidney transplant for 2 kidneys 
if required? 
      In hours          Out of hours  
 
Would you cancel elective transplant for a DD kidney transplant?   
             Yes                         No  
 
Does the unit have dedicated anaesthetic team for kidney transplant? 
       In hours          Out of hours  
 
 
No of dedicated beds available for DD kidney transplants: 
ICU beds          HDU beds         Ward beds   
 
What are the factors that affect your ability to take the patient to theatre for transplant? 
Surgeon availability  
Theatre availability   











        
 
 
The first 4 months of the pilot study are now complete and it is being rolled out 
nationally. 4 transplant centres (Edinburgh, Glasgow, Cambridge and Nottingham), 5 
H&I laboratories (Edinburgh, Glasgow, Cambridge, Oxford and Sheffield) and 2 SN-
OD offices (Scotland and Eastern Organ Donation Services) participated in the pilot 
study, the main purpose of which was to ensure that the data collection forms are fit for 
purpose 



















































MINIMISING COLD ISCHAEMIA TO MAXIMISE OUTCOMES 




























RC Form H&I Form 
Edinburgh 54-78% 56-100% 
Glasgow 57-92% 78-100% 
Cambridge 73-96% 92-100% 
Nottingham 92-100% N/A 
Sheffield N/A 85-100% 
Oxford N/A 62-100% 

























































MINIMISING COLD ISCHAEMIA TO MAXIMISE OUTCOMES IN 















Welcome to the second newsletter of the national cold ischaemic time (CIT) 
project for six months between June and November 2011. The project is now well 
underway nationally with 21 transplant centres and 19 Histocompatibility and 














































A total of 851 deceased donor 
kidney only and SPK transplants 
were performed in the United 
Kingdom within the 6 month 
period. In addition to the data 
collected from the ODT, we 
received some data for 570 out of 
the 851 transplants, ie., 66.98% of 
the total transplants in the period.   
 
 
We continue to collect data from 
the following sources: 
 
1. ODT / Specialist Nurse for 
Organ Donation (SNODs) 
2. Transport service providers 
3. H&I staff 
4. Recipient coordinators 




Donor data is collected on core 
donor data from ODT as well as 
from the SNODs at Scottish and 
Eastern Organ Donation Services. 
Transport data is also collected 













Contribution to the Project by Centres Expressed as % of Completion of Forms by 
Recipient Coordinators / Transplanting Surgeons and H&I Staff for 6 months since 
















































































































ll units have been approached for the project. 21 out of 23 transplant units have been 
 
A
visited and a further unit has agreed to participate without a visit. 15 out of 20 H&I 
laboratories are fully engaged with the project and are returning forms. 13 out of 23 
transplant units (recipient coordinators and transplant surgeons) are also fully 
engaged. 
 
 
 
Thank you 
 
Kind regards 
Sussie 
 
Sussie Shrestha 
Clinical Research Fellow 
Royal Infirmary of Edinburgh 
51 Little France Crescent 
Edinburgh 
EH16 4SA 
 
 
Email: sussie.shrestha@nhs.net 
Tel: 07875500726 (Mobile) 
 
 
